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Abstract
Bacterial opportunistic human pathogens frequently exhibit intrinsic antibiotic tolerance and
resistance, resulting in infections that can be nearly impossible to eradicate. We asked
whether this recalcitrance could be driven by these organisms’ evolutionary history as envi-
ronmental microbes that engage in chemical warfare. Using Pseudomonas aeruginosa as a
model, we demonstrate that the self-produced antibiotic pyocyanin (PYO) activates
defenses that confer collateral tolerance specifically to structurally similar synthetic clinical
antibiotics. Non-PYO-producing opportunistic pathogens, such as members of the Burkhol-
deria cepacia complex, likewise display elevated antibiotic tolerance when cocultured with
PYO-producing strains. Furthermore, by widening the population bottleneck that occurs dur-
ing antibiotic selection and promoting the establishment of a more diverse range of mutant
lineages, PYO increases apparent rates of mutation to antibiotic resistance to a degree that
can rival clinically relevant hypermutator strains. Together, these results reveal an over-
looked mechanism by which opportunistic pathogens that produce natural toxins can dra-
matically modulate the efficacy of clinical antibiotics and the evolution of antibiotic
resistance, both for themselves and other members of clinically relevant polymicrobial
communities.
Introduction
The emergence and spread of bacterial resistance to clinical antibiotics is a growing public
health concern worldwide [1]. Moreover, it is increasingly appreciated that antibiotic tolerance
can also contribute to the failure of treatments for infections [2] and that tolerance can lead to
the evolution of resistance [3,4]. Yet bacterial resilience to antibiotics is anything but new:
Microbes in environments like soil have been producing natural antibiotics and evolving
mechanisms of tolerance and resistance for millions of years [5,6]. Here, we define tolerance as
PLOS BIOLOGY
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the ability to survive a transient exposure to an otherwise lethal antibiotic concentration and
resistance as the ability to grow in the presence of an antibiotic, similar to recent recommenda-
tions [2,7,8].
Considering that most of the antibiotics used today are derived from microbially produced
molecules, we hypothesized that molecular defenses that originally evolved to protect cells
from a natural antibiotic in the environment might also promote tolerance and/or resistance
to structurally or mechanistically similar clinical drugs. Indeed, several clinical antibiotic resis-
tance genes are thought to have originated in nonpathogenic soil bacteria, but it has often been
assumed that intermediate steps of horizontal gene transfer are necessary in order for such
genes to be acquired by human pathogens [6]. In this study, we asked whether there could be a
direct link between production of natural antibiotics by an opportunistic human pathogen and
its recalcitrance to clinical antibiotic treatment due to shared protective mechanisms. In addi-
tion, we sought to determine whether in the presence of such a natural antibiotic producer,
recalcitrance to clinical antibiotics could also be observed in other opportunistic pathogens
found together with it in polymicrobial infections. Given that many opportunistic pathogens
share their natural environment (e.g., soil), we posited that the evolutionary legacy of natural
antibiotic–mediated ecological interactions between these microbial species could have impor-
tant implications for antibiotic tolerance and resistance in the clinical context.
One organism that is well suited to testing these hypotheses is the opportunistic pathogen
Pseudomonas aeruginosa, which is notorious for causing chronic lung infections in cystic
fibrosis (CF) patients, as well as other types of infections in immunocompromised hosts [9]. P.
aeruginosa produces several redox-active, heterocyclic compounds known as phenazines [10].
Phenazines have been shown to provide multiple benefits for their producers, including by (i)
serving as an alternative electron acceptor in the absence of oxygen, thereby promoting redox
homeostasis and anaerobic survival [11], which is particularly relevant for oxidant-limited bio-
films [12]; (ii) acting as signaling molecules [13]; (iii) promoting iron acquisition [14]; and (iv)
killing competitor species [15]. In addition, despite possessing broad-spectrum antimicrobial
activity [10], including against P. aeruginosa itself [16], phenazines have recently been shown
to promote tolerance to clinical antibiotics under some circumstances, via mechanisms that
have yet to be characterized [17,18]. Here, we sought to assess potential broader implications
of this phenomenon by investigating whether phenazine-mediated tolerance to clinical antibi-
otics in P. aeruginosa is driven by cellular defenses that evolved to mitigate self-induced toxic-
ity. We also tested whether phenazine production by P. aeruginosa could promote antibiotic
tolerance in other clinically relevant opportunistic pathogens from the Burkholderia and Steno-
trophomonas genera. Finally, we explored the ramifications of phenazine-induced tolerance
for the evolution of heritable antibiotic resistance, both in P. aeruginosa and in a clinical isolate
from the Burkholderia cepacia complex.
Results
Mechanisms of tolerance to the self-produced natural antibiotic PYO in P.
aeruginosa
We started by characterizing the defense mechanisms P. aeruginosa has evolved to tolerate its
most toxic self-produced phenazine, pyocyanin (PYO) [10,16]. To do so in an unbiased fash-
ion, we performed a genome-wide transposon sequencing (Tn-seq) screen in which the
mutant library was exposed to PYO under starvation to maximize PYO toxicity [16], and toler-
ance of the pooled mutants to PYO was assessed following regrowth (Fig 1A). This revealed 5
broad categories of genes that significantly affect tolerance to PYO: (i) efflux system repressors;
(ii) protein damage responses; (iii) membrane or cell wall biosynthesis; (iv) oxidative stress
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Fig 1. Mechanisms of tolerance to the self-produced natural antibiotic PYO in P. aeruginosa. (A) Genome-wide Tn-seq experimental design.
Cells were incubated with and without PYO under nutrient starvation for maximum PYO toxicity [16] (see Methods for details). Bar graphs shown
are hypothetical representations of the expected results for genes with different fitness effects and are not derived from the obtained data. (B)
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responses; and (v) carbon metabolism and transport (Fig 1B). We validated the screen results by
constructing and testing chromosomal clean deletion mutants for four of these genes (Fig 1C).
The fitness effects of different transposon insertions largely aligned with what is thought to
be the primary mode of PYO toxicity, which is the generation of reactive oxygen species (ROS)
[19,20]. For example, the fact that transposon insertions in different genes within the “carbon
metabolism and transport” category had opposite effects on fitness likely reflects conflicting
priorities for cells challenged with ROS-generating toxins: On the one hand, limiting flux
through the electron transport chain decreases the potential for ROS generation, but on the
other hand, proton motive force is required to pump the toxin out, and NADH is needed to
power reductases involved in repair of oxidative damage. The need to counteract oxidative
stress would also explain why transposon insertions in genes related to protein damage repair
and glutathione synthesis or reduction led to decreased fitness in the presence of PYO (Fig
1B). Finally, for genes related to cell wall/membrane synthesis, the transposon insertions may
have altered cellular permeability and thereby either increased or decreased PYO influx.
However, the strongest hits in our Tn-seq were transposon insertions in transcriptional
repressors of resistance-nodulation-division (RND) efflux system genes (Fig 1B, S1 Table),
which would cause overexpression of the downstream efflux pumps. These insertions dramati-
cally increased fitness in the presence of PYO, suggesting that one of the most effective
defenses against PYO toxicity is to decrease the intracellular concentration of the toxin. While
transposon insertions in the genes encoding the efflux pump proteins themselves did not have
strong effects in our screen (S1 Table), this is likely due to partial functional redundancy
among the various efflux systems [21]. Indeed, when we challenged starved P. aeruginosa with
PYO in the presence of the broad-spectrum RND efflux inhibitor phenylalanine-arginine β-
naphthylamide (PAβN), cell death was accelerated, confirming that efflux pumps are necessary
for minimizing PYO toxicity (Fig 1D).
Mutations in the efflux system repressors identified in our Tn-seq screen are commonly
found in clinical isolates that are resistant to synthetic fluoroquinolone antibiotics, as the efflux
systems regulated by these repressors efficiently export this class of drugs [22,23]. We therefore
asked whether the mechanisms used by P. aeruginosa to tolerate PYO toxicity might overlap
more broadly with those that confer tolerance to fluoroquinolones. To address this question,
we compared our dataset to a recent Tn-seq study that screened for genes that affect P. aerugi-
nosa survival in the presence of the broad-spectrum fluoroquinolone ciprofloxacin [24].
Across the 2 datasets, we observed similar fitness effects for insertions in a small number of
genes within the “protein damage response,” “membrane/cell wall,” and “oxidative stress
response” categories, but the most dramatic fitness increases in both experiments were caused
by insertions in a shared set of efflux system repressors (Fig 1E, S1 Table). These results
highlighted the potential for a conserved molecular route to increased tolerance against both a
natural antibiotic, PYO, and a synthetic clinical antibiotic, ciprofloxacin.
Statistically significant fitness effects of transposon insertions in different representative genes under conditions that maximize PYO toxicity (for full
dataset, see S1 Table). See Methods for details on calculation of fitness. Asterisks show genes for which chromosomal clean deletion mutants were
constructed and validated. (C) Tn-seq validations. Chromosomal clean deletion mutants were exposed to PYO under carbon starvation, similar to
the conditions used for the Tn-seq experiment. Survival of each strain was measured by CFUs and compared to the survival of the parent Δphz strain
for fitness calculation (see Methods for details). Statistical significance was calculated using 1-way ANOVA with Tukey HSD multiple comparison
test, with asterisks showing significant differences relative to Δphz (��� p< 0.001). Data points represent independent replicates, and black
horizontal lines mark the mean fitness for each strain. (D) Tolerance to PYO toxicity in the presence and absence of the efflux inhibitor PAβN. Each
data point represents an independent biological replicate (n = 4), and the horizontal black lines mark the mean survival for each condition and time
point. (E) Fitness correlation analysis between PYO tolerance Tn-seq (this study) and CIP persistence Tn-seq [24]. Efflux repressors present in both
datasets are highlighted in green. For full analysis, see S1 Table. The data underlying this figure can be found in Table A in S1 Data. ANOVA,
analysis of variance; CFU, colony-forming unit; CIP, ciprofloxacin; HSD, honestly significant difference; PAβN, phenylalanine-arginine β-
naphthylamide; PYO, pyocyanin; Tn-seq, transposon sequencing.
https://doi.org/10.1371/journal.pbio.3001093.g001
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PYO induces expression of specific efflux systems, conferring cross-
tolerance to fluoroquinolones
Given that cellular processes involved in PYO tolerance have also been implicated in ciproflox-
acin tolerance, we asked whether exposure to PYO could promote an increase in tolerance to
ciprofloxacin and related clinical antibiotics, including other synthetic fluoroquinolones.
Importantly, such an effect would require that PYO induces the expression of shared defense
mechanisms. We have previously established that PYO up-regulates expression of not only the
oxidative stress response genes ahpB (an alkyl hydroperoxide reductase) and katB (a catalase)
[16], but also at least 2 efflux systems known to pump fluoroquinolones,mexEF-oprN and
mexGHI-opmD [13,16]. We confirmed these expression patterns by performing quantitative
reverse transcriptase PCR (qRT-PCR) on the wild-type (WT) strain that produces PYO, a
Δphzmutant that does not produce PYO, and Δphz treated with exogenous PYO (S1–S3 Figs).
Notably, phenazines and fluoroquinolones both contain at least 1 aromatic ring, unlike other
antibiotics that are not thought to be pumped bymexEF-oprN andmexGHI-opmD, such as
aminoglycosides [21] (Fig 2A). Thus, structural similarities could account for why efflux
pumps that likely evolved to export natural antibiotics such as PYO can also transport certain
classes of synthetic antibiotics. To determine whether PYO also induces other efflux systems
known to pump clinical antibiotics besides fluoroquinolones, we performed qRT-PCR on rep-
resentative genes from all 11 major RND efflux systems in the P. aeruginosa genome. These
measurements confirmed thatmexEF-oprN andmexGHI-opmD are the only 2 efflux systems
significantly induced by PYO and that the induction is PYO dose dependent (Fig 2B, S2 and
S3 Figs). ThemexGHI-opmD system in particular reached expression levels comparable to the
constitutively expressedmexAB-oprM efflux system (Fig 2B, S2 Fig), which plays an important
role in the intrinsic antibiotic tolerance and resistance of P. aeruginosa [21].
To assess whether the induction of efflux pumps and oxidative stress responses by PYO
could increase the tolerance of P. aeruginosa to clinical drugs such as ciprofloxacin, we grew
cultures with or without clinically relevant concentrations of PYO [25] and performed a sur-
vival assay following treatment with different antibiotics. Importantly, we hypothesized that
PYO would not be a universal antagonist to all clinical antibiotics. Instead, we expected toler-
ance to increase only for drugs affected by the defense mechanisms induced by PYO in the
cells. Indeed, compared to the non-PYO-producing Δphzmutant, the PYO-producing WT
strain and PYO-treated Δphz were more tolerant to both ciprofloxacin and another fluoro-
quinolone, levofloxacin (Fig 2C). On the other hand, PYO did not confer increased tolerance
to (i) aminoglycosides (Fig 2D, S4B Fig), which are not substrates for the efflux pumps up-reg-
ulated by PYO [21]; or (ii) colistin (polymyxin E) (Fig 2C), an antimicrobial peptide that per-
meabilizes the outer membrane of the cell by interacting with the lipopolysaccharide and
causing displacement of divalent cations [1]. Similar to aminoglycosides, colistin is not known
to be pumped by the PYO-induced efflux systems [21]; moreover, efflux rarely impacts poly-
myxin efficacy [26]. PYO itself was not toxic under the experimental conditions used in our
tolerance assays [16] (S4C Fig). Aside from PYO, 1-hydroxyphenazine was the only other
phenazine made by P. aeruginosa that increased tolerance to ciprofloxacin under our condi-
tions, albeit to a lesser extent than PYO (Fig 2E). We also tested whether the presence of PYO
could affect the minimum inhibitory concentration (MIC) for ciprofloxacin, as the classical
definition of antibiotic tolerance also stipulates that increased survival in the presence of an
antibiotic is not accompanied by an increase in MIC [2,8]. When we determined the MIC
for ciprofloxacin according to standard clinical protocols [27] for our P. aeruginosa strain in
the presence or absence of PYO, we saw no consistent difference at a detection limit of a
2-fold increase in MIC (S7 Table), supporting the interpretation that the effect of PYO on
PLOS BIOLOGY Bacterially-produced toxin promotes antimicrobial tolerance and resistance
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Fig 2. PYO induces expression of specific efflux systems, conferring cross-tolerance to fluoroquinolones. (A)
Structures of PYO, 2 representative fluoroquinolones (CIP and LVX) and 2 representative aminoglycosides (GEN and
TOB). PYO and fluoroquinolones are pumped by MexEF-OprN and MexGHI-OpmD, while aminoglycosides are not
[21,22]. Rings with an aromatic character are highlighted in red. (B) Normalized cDNA levels for genes within operons
coding for the 11 main RND efflux systems in P. aeruginosa (left; n = 3) and PYO-dose-dependent changes in
expression ofmexEF-oprN andmexGHI-opmD systems (right; n = 3). For full qRT-PCR dataset, see S1–S3 Figs. (C)
Effect of PYO on tolerance to CIP (1 μg/mL), LVX (1 μg/mL), and CST (16 μg/mL) in GMM (n = 4). (D) Effect of PYO
on tolerance to CIP (1 μg/mL) and TOB (40 μg/mL) in SCFM (n = 4). PYO itself was not toxic under the experimental
conditions [16] (S4C Fig). WT made 50–80 μM PYO as measured by absorbance of the culture supernatant at 691 nm.
See S5A Fig for experimental design. (E) Effect on tolerance to CIP (1 μg/mL) in GMM caused by the presence of the 4
main phenazines produced by P. aeruginosa (PYO, PCA, PCN, and 1-OH-PHZ) (n = 4). For this experiment, a Δphz�
strain that cannot produce or modify any phenazine was used (see Methods). (F, G) Effect of PYO on lag during
outgrowth after exposure to CIP in GMM. A representative field of view over different time points (F; magenta = WT::
mApple, green = Δphz::GFP; see S1 Movie) is shown together with the quantification of growth area on the agarose
pads at time 0 hour and 15 hours (G). For these experiments, a culture of each strain tested was grown and exposed to
CIP (10 μg/mL) separately, then cells of both cultures were washed, mixed, and placed together on a pad and imaged
during outgrowth. The pads did not contain any PYO or CIP (see Methods and S5D Fig for details). White arrows in
the displayed images point to regions with faster recovery of WT growth. The field of view displayed is marked with a
black arrow in the quantification plot. The results for the experiment with swapped fluorescent proteins are shown in
S4E Fig. See S4C Fig for complementary data about effects of PYO on lag. Scale bar: 20 μm. (H) Tolerance of Δphz to
CIP (1 μg/mL) in GMM in the presence of different concentrations of PYO (n = 4). (G) Tolerance of Δphz to CIP
(1 μg/mL) in GMM upon artificial induction of themexGHI-opmD operon with arabinose (n = 4). The dashed green
line marks the average survival of PYO-producing WT under similar conditions (without arabinose). Statistics: C, D,
E, H—1-way ANOVA with Tukey HSD multiple comparison test, with asterisks showing significant differences
relative to untreated Δphz (no PYO); G, I—Welch unpaired t test (� p< 0.05, �� p< 0.01, ��� p< 0.001, n.s. p> 0.05).
In all panels with quantitative data, black horizontal lines mark the mean value for each condition. Individual data
points represent independent biological replicates, except for in panel G, where the data points represent different
PLOS BIOLOGY Bacterially-produced toxin promotes antimicrobial tolerance and resistance
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P. aeruginosa is primarily an increase in antibiotic tolerance (i.e., survival without the ability to
grow) rather than phenotypic resistance. Importantly, PYO also induced ciprofloxacin toler-
ance when P. aeruginosa was grown in synthetic cystic fibrosis sputum medium (SCFM) (Fig
2D), suggesting that PYO production could contribute to antibiotic tolerance of this bacterium
in CF patients. Together, these results indicate that PYO preferentially induces tolerance to
fluoroquinolones.
Under in vitro conditions, PYO is typically produced in early stationary phase [13]. However,
the heterogeneous nature of physiological conditions in infections [28,29] could lead to intermix-
ing of PYO-producing and PYO-non-producing cells in vivo. We therefore tested whether exoge-
nous PYO could increase the fluoroquinolone tolerance of cells harvested during log phase,
which did not make PYO. To limit the growth of the no-antibiotic control, we exposed these cells
to the antibiotics under nitrogen depletion. PYO still increased tolerance to both ciprofloxacin
and levofloxacin under these conditions, suggesting that the induced tolerance phenotype does
not depend on the previous growth phase of growth-arrested cells [16] (S4B Fig). Next, to visual-
ize the recovery of cell growth after a transient exposure to ciprofloxacin, we performed a time-
lapse microscopy assay (S4D Fig). Interestingly, WT P. aeruginosa and PYO-treated Δphz exhib-
ited a shorter lag phase compared to non-PYO-treated Δphz following ciprofloxacin treatment
(Fig 2F and 2G, S4E and S4F Fig, S1 Movie), suggesting that PYO-induced defenses may help
minimize cellular damage during the antibiotic treatment. We also found that addition of PYO
to Δphz increased ciprofloxacin tolerance in a dose-dependent manner (Fig 2H), mirroring the
dose-dependent induction ofmexEF-oprN andmexGHI-opmD (Fig 2B).
Given that PYO-induced efflux pumps transport specific substrates [21], we asked if
increased drug efflux could be the primary mechanism underlying PYO-mediated tolerance to
fluoroquinolones. At high concentrations of ciprofloxacin, addition of the efflux inhibitor
PAβN eliminated the survival advantage of PYO-treated cells, indicating that efflux pump activ-
ity is necessary for the PYO-mediated increase in antibiotic tolerance (S4G Fig). Next, we con-
structed a Δphz strain with themexGHI-opmD operon under the control of an arabinose-
inducible promoter (Para:mexGHI-opmD). We verified that the transcription levels ofmexGHI-
opmD under arabinose induction were comparable to when PYO is present (S5 Fig). Indeed,
arabinose induction ofmexGHI-opmD expression increased ciprofloxacin tolerance to near WT
levels (Fig 2I), suggesting that induction of this efflux system is sufficient to confer the PYO-
mediated increase in tolerance. On the other hand, arabinose induction of the oxidative stress
response genes ahpB or katB did not significantly increase tolerance of Δphz to ciprofloxacin
(S6A and S6B Fig); however, the levels of induction achieved for these 2 genes with arabinose
were lower than those observed in the presence of PYO (S1–S5 Figs). Importantly, the clinical
relevance ofmexGHI-opmD was previously not well known; as to our knowledge, there have
been no reports of clinical mutants with constitutive overexpression of this efflux system. Taken
together, our results demonstrate that PYO-mediated regulation ofmexGHI-opmD expression
modulates tolerance to a particular class of clinically used antibiotics in P. aeruginosa.
PYO promotes the evolution of antibiotic resistance in P. aeruginosa
Previous studies have demonstrated that mutations conferring antibiotic tolerance or persis-
tence promote the evolution of antibiotic resistance [3,4]. Moreover, tolerance mutations can
fields of view. The data underlying this figure can be found in Table B in S1 Data. 1-OH-PHZ, 1-hydroxyphenazine;
ANOVA, analysis of variance; CIP, ciprofloxacin; CST, colistin; GEN, gentamicin; GMM, glucose minimal medium;
HSD, honestly significant difference; LVX, levofloxacin; PCA, phenazine-1-carboxylic acid; PCN, phenazine-
1-carboxamide; PYO, pyocyanin; qRT-PCR, quantitative reverse transcriptase PCR; RND, resistance-nodulation-
division; SCFM, synthetic cystic fibrosis sputum medium; TOB, tobramycin; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3001093.g002
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(i) interact synergistically with resistance mutations to increase bacterial survival during anti-
biotic treatment [30]; and (ii) promote the establishment of resistance mutations during com-
bination drug therapy [31]. To assess whether antibiotic tolerance induced by PYO could
similarly promote the establishment of resistance mutations in populations of P. aeruginosa
undergoing extended exposure to a clinical antibiotic, we next performed a series of fluctua-
tion tests (Fig 3A). In clinical settings, antibiotic resistance is likely to result in treatment fail-
ure if a pathogen can grow at antibiotic concentrations above a threshold commonly referred
to as a “breakpoint.” We adopted this criterion by selecting mutants on antibiotic concentra-
tions equal to or higher than the breakpoints defined by the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST) [32]. Furthermore, we added PYO to our cultures
either prior to the antibiotic selection step and/or concurrently with the antibiotic selection, in
order to distinguish between the effects of preemptive versus continuous induction of PYO-
regulated cellular defenses. Finally, while mutation rates inferred from fluctuation tests have
sometimes been assumed to correlate with the per-base mutation rate across the genome
[33,34], the results from these assays are also affected by the number of unique possible muta-
tions that permit growth under the selection condition [35]. To encompass both possibilities
in this study, we use the term μapp (apparent rate of mutation) as a proxy for the likelihood of
evolving antibiotic resistance. We calculated this parameter using standard methods for fluctu-
ation test analysis (see Methods for details).
Regardless of whether PYO was added prior to or concurrently with the antibiotic selection,
PYO significantly increased μapp for resistance to ciprofloxacin in log-phase cultures (Fig 3B,
S2 and S3 Tables). The same trends were also observed in stationary-phase cultures, albeit with
smaller effect sizes (S7A Fig). These results indicate that pretreatment with PYO is sufficient
but not necessary to increase μapp for ciprofloxacin resistance. Adding PYO at both stages of
the fluctuation test generally resulted in an even greater increase in μapp (Fig 3B, S7A Fig), and
the increase in μapp when PYO was added prior to antibiotic selection was dose dependent (Fig
3C). Cultures that were selected on levofloxacin similarly displayed an increased μapp upon
PYO treatment, although the impact of pretreatment versus co-treatment with PYO varied
across biological replicates (Fig 3B, S2 and S3 Tables). More importantly, PYO significantly
increased μapp for cultures that were grown in liquid SCFM and selected on SCFM plates con-
taining ciprofloxacin (Fig 3D, S3 Table), suggesting that PYO produced by P. aeruginosa could
promote mutation to antibiotic resistance in chronically infected lungs of CF patients [36].
Because PYO did not increase tolerance to aminoglycosides (Fig 2D, S4B Fig), we hypothe-
sized that PYO would not promote mutation to aminoglycoside resistance if the induction of
shared defense mechanisms was required for the observed increases in μapp. On the other
hand, if PYO affected μapp primarily by acting as a mutagen, pretreatment with PYO before
antibiotic selection would be expected to increase μapp by a similar proportion for resistance to
all classes of antibiotics. To differentiate between these modes of action, we repeated the fluctu-
ation tests using gentamicin and tobramycin, representative members of the aminoglycoside
class that disrupt protein translation [1]. Cultures that were preexposed to PYO consistently
exhibited significant increases in μapp for gentamicin resistance (Fig 3E, S2 and S3 Tables). For
tobramycin resistance, on the other hand, pretreatment with PYO only significantly
increased μapp in one out of 4 biological replicates (Fig 3E, S2 and S3 Tables). In addition, for
both aminoglycosides, adding PYO to the antibiotic selection plates had no effect on μapp in
most replicates (Fig 3E, S2 and S3 Tables). These differing responses to PYO depending on the
choice of clinical antibiotic suggested that the observed changes in μapp were related to PYO-
induced cellular defenses more so than a mutagenic effect of PYO. In fact, previous studies
have suggested that gentamicin generates ROS more readily than tobramycin [37,38]. This
could account for why the effect of pre-exposure to PYO on μapp for resistance was greater for
PLOS BIOLOGY Bacterially-produced toxin promotes antimicrobial tolerance and resistance
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Fig 3. PYO increases the apparent rate of mutation to antibiotic resistance in P. aeruginosa. (A) Experimental
design for fluctuation tests to determine the effect of PYO (100 μM unless otherwise noted) on apparent mutation
rates. For panels B–E, mutation rates were calculated using an established maximum likelihood-based method that
accounts for the effects of plating a small proportion of the total culture volume (see Methods for details). Each data
point in those panels represents a single biological replicate comprising 44 parallel cultures, and the vertical lines
represent the 84% confidence intervals. Lack of overlap in these confidence intervals corresponds to statistical
significance at the p< 0.05 threshold [99]. For statistical significance as determined by a likelihood ratio test, see S2
Table. In B, D, and E, the PYO treatments correspond to the following: −/− denotes no PYO pretreatment (in the
liquid culture stage) or co-treatment (in the antibiotic agar plates), +/− denotes PYO pretreatment but no co-
treatment, −/+ denotes PYO co-treatment without pretreatment, and +/+ denotes both PYO pretreatment and co-
treatment. (B) Apparent mutation rates of log-phase Δphz grown in GMM and plated on MH agar containing CIP
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gentamicin than for tobramycin, given that PYO primes cells to detoxify ROS by inducing oxida-
tive stress responses (S1 Fig). For resistance to fluoroquinolones, on the other hand, simultaneous
induction of multiple defenses is likely necessary to recapitulate the increases in μapp upon expo-
sure to PYO. Overexpression of individual oxidative stress genes induced by PYO did not
increase μapp for ciprofloxacin resistance, while overexpression of themexGHI-opmD efflux sys-
tem only mildly increased μapp in a subset of biological replicates (S7B Fig). Interestingly, the latter
result contrasted with our finding that induction ofmexGHI-opmDwas sufficient to recapitulate
PYO-mediated increases in fluoroquinolone tolerance. Together, our data suggest that while tol-
erance and resistance can be mechanistically interrelated, overcoming the barrier to growing in
the presence of an antibiotic in some cases requires a different or broader set of defenses than is
required for temporary survival under growth-arrested conditions. Nevertheless, PYO-induced
defense mechanisms appear to contribute to both types of resilience to antibiotic treatment.
We envisioned at least 3 ways in which, under antibiotic selection, PYO-induced defense
mechanisms could lead to the apparent increases in mutation rates: (A) by enhancing the
growth of preexisting “partially resistant” mutants during exposure to the antibiotic; (B) by
increasing the proportion of cells that survive and subsequently mutate to resistance while still
in the presence of the antibiotic; or (C) by a combination of A and B. To distinguish between
these scenarios, we implemented a 2-pronged approach. First, to explore the possibility of sce-
nario A, we isolated and characterized several mutants from the fluctuation test plates contain-
ing ciprofloxacin. We regrew the isolates under nonselective conditions both with and without
PYO treatment and calculated the percentage of colony-forming units (CFUs) that could sub-
sequently be recovered on ciprofloxacin plates relative to nonselective plates, as a metric for
each isolate’s level of resistance. We defined as “partially resistant” those isolates for which
only a subset of the population could grow under the antibiotic selection without PYO treat-
ment, as evidenced by lower CFU counts on antibiotic plates compared to nonselective plates.
Second, to determine the relative likelihoods of scenario A and scenario B, we examined the fit
of our fluctuation test data to different formulations of the theoretical Luria–Delbrück (LD)
distribution. Specifically, we compared mathematical models that make different assumptions
regarding whether mutants arise prior to or during the antibiotic selection.
We identified multiple partially resistant mutants for which the percentage of CFUs recov-
ered on ciprofloxacin plates following growth under nonselective conditions increased when
the isolate was either preexposed or co-exposed to PYO (Fig 4A), although the trends were not
always statistically significant. Importantly, CFUs for the Δphz parent strain were below the
level of detection on the ciprofloxacin plates even in the presence of PYO, confirming that
PYO-induced defenses alone, in the absence of a resistance mutation, were insufficient to
enable growth under the selection condition used for the fluctuation tests (Fig 4A). In addition,
for all characterized partially resistant mutants, the MIC for ciprofloxacin was higher than for
the parent strain (S7 Table). For some of these mutants, the MIC determined according to
standard clinical protocols [27] matched the ciprofloxacin concentration originally used for
selection, even in the presence of PYO, but this is not surprising, as the relatively dilute
(0.5 μg/mL; n = 4) or LVX (1 μg/mL; n = 5), with or without pre- and/or co-exposure to PYO relative to the antibiotic
selection step. (C) The apparent rate of mutation to resistance for Δphz cells that were pretreated with different
concentrations of PYO in GMM and plated onto MH agar containing CIP (0.5 μg/mL). (D) Apparent mutation rates
of log-phase Δphz grown in SCFM and plated on SCFM agar containing CIP (1 μg/mL; n = 4) with or without pre-
and/or co-exposure to PYO. (E) Apparent mutation rates of log-phase Δphz grown in GMM and plated during onto
MH agar containing GEN (16 μg/mL; n = 4) or TOB (4 μg/mL; n = 4), with or without pre- and/or co-exposure to
PYO. The data underlying this figure can be found in Table C in S1 Data. CIP, ciprofloxacin; GEN, gentamicin; GMM,
glucose minimal medium; LVX, levofloxacin; MH, Mueller–Hinton; PYO, pyocyanin; SCFM, synthetic cystic fibrosis
sputum medium; TOB, tobramycin.
https://doi.org/10.1371/journal.pbio.3001093.g003
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inoculum (5 × 105 CFU/mL) and short incubation time (18 hours) used for standard MIC
assays can preclude detection of weak growth at a given antibiotic concentration. As a further
validation of our assay for detection of partially resistant mutants, we also tested isolates with
distinct colony morphologies that were not enriched on the PYO-containing antibiotic plates
relative to PYO-free antibiotic plates in the original fluctuation tests. As expected, these
mutants were fully resistant to ciprofloxacin at the original selection concentration (S8A Fig),
meaning that the same number of CFUs grew on both antibiotic plates and nonselective plates
even in the absence of PYO. Interestingly, the effect of PYO on ciprofloxacin resistance varied
across different partially resistant isolates (Fig 4A). This suggests that PYO does not universally
raise the level of resistance of the entire population, but rather interacts synergistically with
specific types of mutations conferring partial resistance. Such heterogeneity could account for
why the effect of PYO in the fluctuation tests varied across biological replicates, as the degree
of benefit conferred by PYO would depend on the specific mutations that randomly occurred
in each replicate. We also repeated the stationary-phase ciprofloxacin tolerance assay with the
Fig 4. PYO promotes the growth of partially resistant mutants and the occurrence of post-plating mutations. (A)
Putative CIP-resistant mutants of P.a. isolated from fluctuation test plates were grown to mid-log phase in liquid
GMM with or without 100 μM PYO, before plating for CFUs on nonselective MH agar plates, plates containing CIP
alone (0.5 μg/mL), and plates containing CIP and PYO. Plotted values represent the percentage of CFUs recovered on
the CIP plates, calculated relative to total CFUs counted on nonselective plates. On the x-axis, “pre” denotes the
presence of PYO in the liquid cultures, and “co” denotes the presence of PYO in the agar plates. Data points represent
independent biological cultures (n = 4). Black horizontal lines mark the mean values for each condition. (B) Goodness
of fit of different mathematical models for P. aeruginosa Δphz fluctuation test data. Data from the fluctuation tests
performed on CIP are plotted for different combinations of PYO in liquid (pretreatment) and PYO in agar (co-
exposure to antibiotic selection). The empirical CDFs of the data (black) are plotted against (1) a variation of the LD
model fit with 2 parameters,m (the expected number of mutations per culture) and w (the relative fitness of mutant
cells vs. WT), as implemented by Hamon and Ycart [44] (pink); (2) a mixed LD and Poisson distribution fit with 2
parameters,m and d (the number of generations that occur post-plating), allowing for the possibility of post-plating
mutations, as implemented by Lang and Murray [45] (blue); and (3) the basic LD distribution model fit only withm, as
implemented by Lang and Murray [45] (gray). In each condition, the plotted experimental data represent the
biological replicate with the lowest chi-squared goodness of fit p-value (i.e., least good fit) for the Hamon and Ycart
model, demonstrating that this model was still a reasonable fit for these samples. Statistics: A—Welch unpaired t tests
with Benjamini–Hochberg correction for controlling false discovery rate (� p< 0.05, �� p< 0.01, ��� p< 0.001, n.s.
p> 0.05). The data underlying this figure can be found in Table D in S1 Data. CDF, cumulative distribution function;
CFU, colony-forming unit; CIP, ciprofloxacin; GMM, glucose minimal medium; LD, Luria–Delbrück; P.a., P.
aeruginosa; PYO, pyocyanin; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3001093.g004
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partially resistant isolates and found that tolerance was likewise differentially affected by PYO
(S8B Fig). Interestingly, the tolerance and resistance phenotypes shared no obvious underlying
pattern, again suggesting that cellular processes that affect resistance do not always equally
effect tolerance and vice versa. Nevertheless, our results demonstrate that under antibiotic
selection, a subset of partially resistant mutants benefits from exposure to PYO.
Whole-genome sequencing revealed that the partially resistant isolates contained mutations
either in the efflux pump repressors nfxB ormexS or in genes that affected growth rate, such as
a ribosomal protein, a C4-dicarboxylate transporter, and a cell wall synthesis gene (S4 Table).
Mutations in nfxB ormexS were also found in the fully resistant isolates (S4 Table), albeit at
different loci compared to the partially resistant isolates. Notably, nfxB is considered a “pathoa-
daptive gene” in which mutations tend to accumulate during chronic infections [39,40]. Muta-
tions inmexS are less common, but have also been detected in clinical isolates [41]. Slow-
growing small-colony variant mutants of P. aeruginosa have likewise been isolated from
patients [42,43]. Thus, the growth benefits conferred by PYO-induced defenses during antibi-
otic selection could be relevant to a variety of clinically adapted strains.
That PYO increases μapp at least in part by promoting the growth of preexisting partially
resistant mutants was further supported by the alternative approach of evaluating the fit of our
data to different mathematical models. Specifically, Pearson chi-squared test indicated that our
data closely fit the Hamon and Ycart model [44] (Fig 4B, S9 Fig, S3 Table), which allows for dif-
ferential fitness of mutants compared to WT cells, but assumes that all mutants arise pre-plat-
ing. However, we could not unequivocally rule out the possibility that post-plating mutations
contributed to the increases in μapp, as a subset of our data also fit a mixed LD–Poisson model
that assumes some mutations occurred during the antibiotic selection step [45] (Fig 4B, S9 Fig,
S3 Table). We also performed growth curves under the culture conditions used in our fluctua-
tion tests prior to the antibiotic selection step, with the addition of the live cell-impermeable
DNA-binding dye propidium iodide (PI) as a marker for cell death. As expected from a previ-
ous study on PYO toxicity [16], cell death was undetectable prior to the sampling time point
used in most of the fluctuation tests (S8D and S8E Fig). Thus, while increased population turn-
over due to stress can also lead to increases in μapp [46], this is unlikely to underlie the effect of
PYO on μapp. Together, these results suggest that the most probable explanation for the PYO-
mediated increases in apparent mutation rates is a combined effect of increased detection of
partially resistant mutants (the proposed scenario A) and increased occurrence of post-plating
mutations resulting from elevated survival on the antibiotic plates (the proposed scenario B).
Importantly, previous studies based on in vitro evolution experiments have demonstrated
that even modest increases in mutation rates, in the range of 2- to 5-fold, significantly affect
the maximum achievable level of antibiotic resistance for diverse bacterial pathogens [47,48].
Moreover, it is well established that partial resistance can rapidly lead to acquisition of full
resistance via secondary mutations [49,50]. Indeed, several putative mutants appeared fully
resistant to ciprofloxacin in our CFU recovery assay despite having been enriched by exposure
to PYO in the fluctuation tests (S8C Fig). This discrepancy could be a result of acquiring sec-
ondary mutations either during growth on the original fluctuation test plates or during the
pre-growth for the CFU recovery assay. Thus, our results suggest that PYO may significantly
affect the rate at which high-level resistance emerges in populations of P. aeruginosa undergo-
ing long-term antibiotic exposure.
PYO promotes antibiotic tolerance in other opportunistic pathogens
While the above experiments were performed with single species cultures, P. aeruginosa is
found in polymicrobial communities in both natural environments (e.g., soil) and clinical
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contexts (e.g., chronic infections) [51–54]. We hypothesized that microbes that frequently
interact with P. aeruginosa would have evolved inducible defense mechanisms against PYO
toxicity and that production of PYO by P. aeruginosamight therefore also increase tolerance
and resistance to clinical antibiotics in these community members. To test this hypothesis, we
focused on the genera Burkholderia and Stenotrophomonas, both of which are (i) soil-borne
gram-negative opportunistic pathogens that are frequently refractory to clinical antibiotic
treatments [55–57]; and (ii) found in coinfections with P. aeruginosa, e.g., in CF patients [58].
Specifically, we tested a plant-derived strain, B. cepacia ATCC 25416; a non-CF clinical isolate
of Stenotrophomonas, Stenotrophomonas maltophilia ATCC 13637; and several clinical isolates
of the 3 most prevalent Burkholderia species found in CF patients [51]: Burkholderia cenocepa-
cia, Burkholderia multivorans, and Burkholderia gladioli (for descriptions of these strains, see
S5 Table).
We first assessed each strain’s intrinsic resistance to PYO (Fig 5A), as we expected that
strong defenses against PYO toxicity would be required in order to benefit from exposure to
this natural antibiotic. Indeed, for S.maltophilia, which was sensitive to PYO (Fig 5A), the
effects of PYO on antibiotic tolerance were complex: The presence of PYO was only beneficial
when ciprofloxacin levels were low (1 μg/mL) (Fig 5B). At a higher concentration of ciproflox-
acin (10 μg/mL), PYO was detrimental in a dose-dependent manner (Fig 5B), suggesting that
the additional stress conferred by PYO outweighed any induction of defense mechanisms
against ciprofloxacin. S.maltophilia also struggled to grow with P. aeruginosa in cocultures
(Fig 5C and 5D), indicating that the conditions under which this species could potentially ben-
efit from PYO are very limited.
B. cepacia, B. cenocepacia, and B.multivorans, on the other hand, were highly resistant to
PYO (Fig 5A). For these 3 species, exogenously added PYO increased tolerance to ciprofloxa-
cin (Fig 5E). Furthermore, for B. cepacia, we confirmed that this effect was PYO dose depen-
dent (Fig 5E). We therefore tested whether P. aeruginosa could induce tolerance to
ciprofloxacin in cocultures with these Burkholderia strains. Using liquid culture plates in
which the 2 species were separated by a permeable membrane (Fig 5C), we found that PYO-
producing P. aeruginosa strongly induced tolerance to ciprofloxacin in the Burkholderia spe-
cies and that the observed tolerance phenotypes were recapitulated by addition of exogenous
PYO to cocultures of Burkholderia and the P. aeruginosa Δphzmutant or to control cultures
with Burkholderia alone in the same setup (Fig 5F). Notably, for B. cenocepacia and B.multi-
vorans, increased ciprofloxacin tolerance was also observed in cocultures with a PYO-produc-
ing strain isolated from a CF patient, P. aeruginosa PA 76–11 (Fig 5F). In addition, even when
cocultured with Burkholderia, the P. aeruginosaWT strain still showed elevated ciprofloxacin
tolerance when compared to the non-PYO-producing Δphzmutant (Fig 5G). This indicates
that the presence of Burkholderia did not alter P. aeruginosa tolerance patterns under our con-
ditions. Finally, similar results were obtained for experiments performed in SCFM, where
either the addition of exogenous PYO (Fig 5H) or coculture with P. aeruginosa (Fig 5I) led to
increased tolerance levels in Burkholderia. Together, these results suggest that PYO produced
by P. aeruginosa in CF patients may decrease the efficacy of ciprofloxacin as a treatment for
multispecies infections.
PYO promotes the evolution of antibiotic resistance in a co-occurring
opportunistic pathogen
We next asked whether PYO could mediate an increase in apparent mutation rate for cipro-
floxacin resistance in Burkholderia species. We chose B.multivorans AU42096 (B.multivorans
1 in Fig 5) as our model strain for these experiments because, among the clinical isolates, it
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Fig 5. PYO promotes antibiotic tolerance in other opportunistic pathogens. (A) Growth in GMM + AA of several strains in the presence of different
concentrations of PYO. Plotted lines represent averages of 4–6 replicates, and shaded areas in gray represent the standard deviation. Burkholderia multivorans 1
= B.multivorans AU42096. For complete information on strains, see S5 Table. (B) Tolerance of S.maltophilia to different concentrations of CIP (1 or 10 μg/
mL) after growth in the presence of different concentrations of PYO (0, 10, or 50 μM) in GMM + AA (n = 4). (C) Schematic depicting the experimental design
for coculture antibiotic tolerance assays (see Methods for details). (D) CFUs recovered from cocultures of P. aeruginosa (PA14 WT and Δphz) and S.
maltophilia (n = 3), showing that the latter struggled to grow in the presence of P. aeruginosa in GMM + AA. (E) Effect of PYO on the tolerance to CIP (10 μg/
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displayed the strongest response to PYO in the ciprofloxacin tolerance assays. Remarkably,
when selecting B.multivoransmutants on ciprofloxacin, we observed PYO-mediated increases
in μapp that were far more dramatic than for P. aeruginosa: Pretreatment with PYO
increased μapp for B.multivorans approximately 10-fold, while co-exposure to PYO in the anti-
biotic plate without pre-exposure increased μapp approximately 40-fold, and the combination
of pre- and co-exposure to PYO increased μapp by 230-fold (Fig 6A, S3 Table). Notably, the
magnitude of the latter effect is on par with observed differences between hypermutators, such
as mutants deficient in the mismatch repair pathway, and their respective parent strains [59–
61]. Moreover, hypermutators of Burkholderia isolated from CF infections are associated with
clinical ciprofloxacin resistance [59]. In light of these observations, our results suggest that
PYO could significantly affect clinical outcomes for coinfections of P. aeruginosa and B.multi-
vorans treated with ciprofloxacin.
To verify that the B.multivorans colonies growing on ciprofloxacin in the presence of PYO
were mutants, and to assess their responses to PYO, we isolated several putative mutants from the
fluctuation test antibiotic plates and tested three in our CFU recovery assay. All three displayed
unique profiles of ciprofloxacin resistance in response to PYO treatment, as well as different maxi-
mal levels of resistance. However, all were more resistant than the WT parent strain in the pres-
ence of PYO, and none were noticeably resistant to ciprofloxacin in this assay without exposure
to PYO (Fig 6B). MIC tests performed according to clinical standards revealed that the MIC of
CipR-1 was indistinguishable from that of the parent strain, while the MIC of CipR-2 was 2-fold
higher than that of the parent strain in the absence of PYO but identical in the presence of PYO
(S7 Table), reflecting the limitations of standard 2-fold antibiotic dilution series for revealing mild
increases in resistance. The MIC of CipR-7, on the other hand, was 8-fold higher than that of the
parent strain, although in the absence of PYO, the MIC of this mutant was still below the cipro-
floxacin concentration used in the fluctuation tests. Notably, for all tested B.multivorans isolates,
including the WT parent, the addition of PYO to the standard MIC tests increased the MIC for
ciprofloxacin by 4- to 8-fold (S7 Table); however, even in the presence of PYO, the MIC for the
parent strain was less than half of the ciprofloxacin concentration used in the tolerance assays,
indicating that the observed tolerance phenotype for this strain cannot be fully explained by phe-
notypic resistance. Interestingly, the percentage of the parent strain population that could grow
on ciprofloxacin in the presence of PYO (Fig 6B) was approximately equal to what would have
been expected from the frequency of colonies detected in the fluctuation tests; moreover, when
the CFU recovery assay was performed for the parent strain, the colonies that grew on ciprofloxa-
cin in the presence of PYO exhibited diverse morphologies. This suggests that much of the parent
strain growth on ciprofloxacin in the presence of PYO may have in fact reflected the growth of
high-frequency spontaneous mutants, rather than background growth of the parent strain itself.
Whole-genome sequencing of the fluctuation test isolates revealed that B.multivorans
CipR-1 possessed mutations in 3 uncharacterized regulatory genes (S6 Table). B.multivorans
mL) in GMM + AA of multiple Burkholderia species isolated from environmental and clinical samples (n = 4). (F) Effect of PYO produced by P. aeruginosa in
cocultures on the tolerance of different Burkholderia species to CIP (10 μg/mL) in GMM + AA. PA14 is our model laboratory strain of P. aeruginosa, while PA
76–11 is a PYO-producing strain of P. aeruginosa isolated from a CF patient. The Burkholderia strains were plated separately for CFUs to assess survival
following treatment with CIP in the cocultures (n = 3). (G) Tolerance of P. aeruginosa PA14 WT and Δphz to CIP (1 μg/mL) when grown in cocultures with B.
multivorans 1 in GMM + AA (n = 3). (H) Effect of PYO on the tolerance to CIP (10 μg/mL) of B.multivorans 1 in SCFM (n = 4). (I) Tolerance to CIP (1 μg/
mL) in SCFM of B.multivorans 1 grown in cocultures with P. aeruginosa PA14 WT, Δphz, or alone with 100 μM PYO added exogenously (n = 3). Statistics: B,
E, F, G, H, I—1-way ANOVA with Tukey HSD multiple comparison test for comparisons of 3 conditions or Welch unpaired t test for comparison of 2
conditions, with asterisks showing the statistical significance of comparisons with the untreated (no PYO or Δphz) condition (� p< 0.05, �� p< 0.01, ���
p< 0.001). In all panels, data points represent independent biological replicates, and black horizontal bars mark the mean values for each condition. The data
underlying this figure can be found in Table E in S1 Data. AA, amino acids; ANOVA, analysis of variance; CF, cystic fibrosis; CFU, colony-forming unit; CIP,
ciprofloxacin; GMM, glucose minimal medium; HSD, honestly significant difference; PYO, pyocyanin; SCFM, synthetic cystic fibrosis sputum medium; WT,
wild-type.
https://doi.org/10.1371/journal.pbio.3001093.g005
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CipR-2 possessed mutations in 2 different homologs of the SpoT/RelA (p)ppGpp synthetase
gene, which is known to affect antibiotic tolerance and resistance [62]. Finally, B.multivorans
CipR-7 possessed a point mutation in DNA gyrase A (S83R), along with a point mutation in a
malto-oligosyltrehalose synthase. Given that DNA gyrase A is the target of ciprofloxacin and
that the specific mutated residue is likely homologous to the T83 residue that was mutated in a
study of fluoroquinolone-resistant mutants in B. cepacia [63], it is intriguing that this mutant
was not able to grow on the original selection concentration of ciprofloxacin in the absence of
Fig 6. PYO promotes antibiotic resistance in B. multivorans. (A) The apparent rate of mutation to resistance when log-phase B.multivorans 1 cells grown in GMM
+ AA were plated on MH agar containing CIP (8 μg/mL), with or without pre- and/or co-exposure to 100 μM PYO relative to the antibiotic selection step. Each data
point represents a biological replicate comprising 44 parallel cultures (n = 4). The vertical lines represent 84% confidence intervals, in which lack of overlap corresponds
to statistical significance at the p< 0.05 level [99]. The PYO treatments correspond to the following: −/− denotes no PYO pretreatment (in the liquid culture stage) or
co-treatment (in the antibiotic agar plates), +/− denotes PYO pretreatment but no co-treatment, −/+ denotes PYO co-treatment without pretreatment, and +/+ denotes
both PYO pretreatment and co-treatment. (B) The percentage of CFUs recovered on CIP plates either with or without PYO in the agar, for exponential phase cultures of
different partially resistant B.multivorans 1 (B.m.) mutants that were pre-grown with or without PYO in liquid cultures in GMM + AA. Plotted values represent the
percentage of CFUs recovered on the CIP plates, calculated relative to total CFUs counted on nonselective plates. On the x-axis, “pre” denotes the presence of PYO in
the liquid cultures, and “co” denotes the presence of PYO in the agar plates. Data points represent independent biological replicates (n = 4), and black horizontal bars
mark the mean values for each condition. (C) Goodness of fit of different mathematical models for B.multivorans 1 fluctuation test data. Data are plotted for different
combinations of PYO in liquid (pretreatment) and PYO in agar (co-exposure to antibiotic selection). The empirical CDFs of the data (black) are plotted against (1) a
variation of the LD model fit with 2 parameters,m (the expected number of mutations per culture) and w (the relative fitness of mutant cells vs. WT), as implemented by
Hamon and Ycart [44] (pink); (2) a mixed LD and Poisson distribution fit with 2 parameters,m and d (the number of generations that occur post-plating), allowing for
the possibility of post-plating mutations, as implemented by Lang and Murray [45] (blue); and (3) the basic LD distribution model fit only withm, as implemented by
Lang and Murray [45] (gray). In each condition, the plotted experimental data represent the biological replicate with the lowest chi-squared goodness of fit p-value (i.e.,
least good fit) for the Hamon and Ycart model. Statistics: B—Welch unpaired t tests with Benjamini–Hochberg correction for controlling false discovery rate (� p< 0.05,
�� p< 0.01, ��� p< 0.001). The data underlying this figure can be found in Table F in S1 Data. AA, amino acids; CDF, cumulative distribution function; CFU, colony-
forming unit; CIP, ciprofloxacin; GMM, glucose minimal medium; LD, Luria–Delbrück; MH, Mueller–Hinton; PYO, pyocyanin; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3001093.g006
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PYO; however, the specific amino acid (AA) substitution in this strain may have resulted in
only a mild disruption of ciprofloxacin binding.
Lastly, we asked whether the B.multivoransmutants we detected primarily arose prior to or
during the antibiotic selection. In all cases, the distribution of mutants closely matched the
Hamon and Ycart formulation of the theoretical LD distribution, suggesting that the detected
mutants arose prior to the antibiotic exposure (Fig 6C, S3 Table). Interestingly, the Hamon
and Ycart model also predicted the average relative fitness of mutants detected in PYO-treated
samples to be significantly lower compared to mutants detected in non-PYO-treated samples
(S3 Table; p< 0.05 for all 3 comparisons between non-PYO-treated and PYO-treated sample
groups, using Welch paired t test with Benjamini–Hochberg corrections for controlling the
false discovery rate). In addition, unlike for P. aeruginosa, the mixed LD–Poisson distribution
that allows for post-plating mutations was a poorer fit than the Hamon and Ycart model for all
PYO-treated B.multivorans samples (Fig 6C, S3 Table). Together, these results suggest that in
B.multivorans, PYO increases μapp by promoting growth of a wider range of mutants that arise
prior to antibiotic selection, including those with slower growth rates.
Discussion
Many clinical antibiotic resistance genes are thought to have originated in environmental
microorganisms as responses to microbial chemical warfare, with subsequent mobilization
into human pathogens via horizontal gene transfer [5,6,64]. Here, we have demonstrated that
tolerance and resistance to clinically relevant concentrations of synthetic antibiotics can also
arise as a collateral benefit of natural antibiotic production by an opportunistic pathogen. P.
aeruginosa is a particularly relevant example of an opportunistic pathogen whose self-pro-
duced natural antibiotics can promote resilience to clinical antibiotics, given the large number
of chronic infections caused by this bacterium worldwide [9] and the fact that PYO has been
detected at concentrations up to 130 μM in lung infection sputum samples [25] and 0.31 mg/g
in infected wound exudate [65]. Notably, treatments for infections caused by P. aeruginosa
and other opportunistic pathogens often fail even when in vitro MIC tests indicate susceptibil-
ity to the chosen antibiotic [58]. Previous studies have attributed this discrepancy to metabolic
and physiological changes within biofilms [66,67], which represent a major form of bacterial
life within infections [68]. Our results suggest that cellular defenses induced by bacterially pro-
duced natural antibiotics may also contribute to in vitro versus in vivo differences in antibiotic
susceptibility, as standard MIC tests are inoculated at a low cell density [32], but P. aeruginosa
typically does not make PYO in vitro until reaching a relatively high cell density [13]. Further-
more, the observation that PYO produced by P. aeruginosa strongly promotes antibiotic toler-
ance and resistance in Burkholderia species could hold important ramifications for the
treatment of coinfections of these organisms in CF patients, for which clear best practices have
yet to be established [58]. In particular, it could be prudent to avoid treating such infections
with antibiotics for which PYO is likely to promote increased tolerance and resistance, such as
fluoroquinolones, chloramphenicol, and trimethoprim/sulfamethoxazole—the latter two also
being known substrates for efflux pumps that we have shown are up-regulated by PYO [9,21].
Interestingly, our finding that PYO does not increase tolerance to aminoglycosides (Fig 2D,
S4B Fig) contrasts with the conclusions of 2 previous studies on phenazine-mediated antibiotic
tolerance, which claimed that phenazines broadly increase tolerance to all classes of antibiotics
except cationic peptides [17,18]. Importantly, however, these studies did not explore whether
or which molecular defense mechanisms are induced by the phenazines and how these
defenses might interact with clinical antibiotics. Moreover, the studies were performed under
very different experimental setups, including different media, which can profoundly impact
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the outcomes of antibiotic susceptibility assays. One study focused on colony biofilms of P.
aeruginosa that produced only phenazine-1-carboxylic acid (PCA) and phenazine-1-carboxa-
mide [17], which are less toxic than PYO [16] and consequently may induce a different set of
cellular responses. Alternatively, the observed increased tolerance to tobramycin in that study
might not be related to molecular defenses induced by phenazines, but rather phenazine-medi-
ated physiological differences under the studied conditions [17]. Phenazines are redox-active
molecules that can promote metabolic activity under oxygen limitation, which occurs within
biofilms [12,17,69]; the specific details of how such metabolic activity might affect antibiotic
tolerance merit further attention. The other previous study found that PYO increased plank-
tonic culture cell densities in the presence of various antibiotics [18], but these experiments
did not directly demonstrate an effect on antibiotic tolerance (i.e., the ability to survive an oth-
erwise lethal antibiotic treatment) [2]. Notably, both studies found that phenazines actually
increase sensitivity to cationic peptides, consistent with our observation that WT P. aeruginosa
is less tolerant to colistin than the Δphz strain. The mechanism of this synergistic lethality war-
rants further investigation. Our results highlight that identifying the cellular defenses induced
by natural antibiotics, not only in the case of P. aeruginosa and phenazines, but also potentially
other opportunistic pathogens and their endogenously produced natural antibiotics, is essen-
tial for accurately predicting clinical antibiotic efficacy.
Our results furthermore suggest that by inducing cellular defenses against specific clinical
antibiotics, PYO widens the population bottleneck that occurs during antibiotic selection. This
effect occurs via a 2-pronged mechanism (Fig 7). First, PYO increases the proportion of cells
that survive short-term antibiotic treatments, which would inherently tend to preserve a
greater range of genetic variation in the post-selection population. Second, PYO promotes the
establishment of a broader range of resistant mutant lineages, which are likely primed to
acquire further stepwise mutations to high-level resistance, yet may otherwise be lost during
extended antibiotic treatment. Interestingly, a recent study demonstrated that lineages of
spontaneous resistant mutants can be lost through stochastic cell death even at antibiotic con-
centrations well below the mutants’ MICs [70]. Thus, besides boosting the growth of partially
resistant mutants whose MICs failed to exceed the antibiotic concentrations used in our fluctu-
ation tests, it is possible that PYO-induced defenses (e.g., enhanced efflux and oxidative stress
responses) also increased apparent mutation rates by decreasing the stochastic loss of individ-
ual spontaneous mutants with higher MICs. In addition, a recent study in Staphylococcus
aureus highlighted the important role that preexisting genetic diversity in the population can
play in shaping the evolution of antibiotic resistance [71]. In particular, even small variations
in efflux-mediated intrinsic resistance of parent strains significantly affected the probability
that a population would evolve resistance under ciprofloxacin selection at the clinical break-
point concentration [71]. Multiple studies have also demonstrated additive or synergistic inter-
actions between increased drug efflux and classical ciprofloxacin resistance mutations [71–73].
We observed a similar phenomenon in our B.multivorans CipR-7 strain, which had acquired
a mutation in the cellular target of ciprofloxacin (i.e., DNA gyrase A), yet still required expo-
sure to PYO in order to grow at the ciprofloxacin concentration on which it was originally
selected (Fig 6B). Together, these findings suggest that microbial production of natural antibi-
otics in the context of an infection could dynamically, and in some cases dramatically, affect
the evolvability of opportunistic pathogens challenged with clinical drugs.
Beyond P. aeruginosa and PYO, our proposed model for collateral benefits of exposure to
natural antibiotics (Fig 7) potentially represents a broader phenomenon among human patho-
gens than has previously been appreciated. Many opportunistic pathogens originate in envi-
ronments like soil [55,74], where they have evolved in the presence of diverse natural
antibiotics [5,6], and P. aeruginosa is not the only pathogen with the capacity to synthesize its
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own antibiotics. For example, Burkholderia species possess the biosynthetic capability to pro-
duce a variety of compounds with antibacterial activity, whose potential clinical significance
has not been explored [75]. If a given natural antibiotic induces expression of a molecular
defense, the only requirement for a consequent increase in tolerance to a clinically relevant
drug would be that the induced defense has some efficacy against the drug—e.g., due to struc-
tural similarities like those shared by PYO and fluoroquinolones. This inference is supported
by recent evidence that certain food additives and synthetic drugs antagonize the efficacy of
specific clinical antibiotics by triggering stress responses in cells, including the induction of
efflux pumps [76] and that exposure to a clinical drug to which a strain is already resistant can
collaterally affect its development of tolerance and resistance to other drugs [77]. In fact, bacte-
rially produced toxic metabolites that promote antibiotic tolerance and resistance in human
Fig 7. Proposed model for how natural antibiotics increase bacterial tolerance and resistance to clinical drugs. In the first scenario (tolerance), cells are exposed to
the clinical drug (pink dots) for a short period of time. Surviving cells will eventually restart growth after the drug is removed. The presence of the natural antibiotic
(bottom) increases tolerance of both WT and partially resistant mutants. In the second scenario (resistance), cells are constantly exposed to the drug for an extended
period of time, and only mutants are maintained in the population. The presence of the natural antibiotic (bottom) widens the population bottleneck and allows partially
resistant mutants to grow under drug selection, preserving a greater range of genetic diversity in the population. WT, wild-type.
https://doi.org/10.1371/journal.pbio.3001093.g007
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pathogens need not be limited to the types of molecules traditionally thought of as natural anti-
biotics. For example, indole secretion by highly antibiotic-resistant spontaneous mutants of
Escherichia coli enables partially resistant mutants within the same species to grow at drug con-
centrations above their own MICs, in part by stimulating efflux pump expression [78]. Unlike
PYO, indole is generally thought of as a signaling molecule rather than a natural antibiotic [79],
although it can likewise be toxic to bacteria at high concentrations [79,80]. Efforts to identify
and characterize additional examples of such metabolites produced by opportunistic human
pathogens could lead to an improved understanding of the modes of antibiotic treatment failure
in clinics and ultimately inform the design of more effective and longer-lived therapies.
Methods
Culture media and incubation conditions
Different culture media were used for different experiments as indicated throughout the Meth-
ods. Succinate minimal medium (SMM) composition was 40 mM sodium succinate (or 20
mM, if specified), 50 mM KH2PO4/K2HPO4 (pH 7), 42.8 mM NaCl, 1 mM MgSO4, 9.35 mM
NH4Cl, and a trace elements solution [81]. Glucose minimal medium (GMM) was identical to
SMM, except with 10 or 20 mM glucose (as specified for different experiments) instead of suc-
cinate. SMM and GMM were prepared by autoclaving all components together for 20 minutes
at 121˚C, except for the carbon source and the 1,000× trace elements stock solution, which
were filter-sterilized and added separately; interestingly, we found that autoclaving MgSO4
with the other components was crucial for consistent PYO production by WT P. aeruginosa
UCBPP-PA14 in GMM. Luria–Bertani (LB) Miller broth (BD Biosciences, San Jose, California,
United States of America) and BBL cation-adjusted Mueller–Hinton (MH) II broth (BD Bio-
sciences) were prepared according to the manufacturer’s instructions (notably with only a 10
minute autoclave step for MH medium), with the addition of 1.5% Bacto agar (BD Biosci-
ences) to make solid media. SCFM composition was prepared as described previously [36],
with 1.355 mM K2SO4 and no nitrate. In addition, 3.6 μM FeSO4.7H2O and 0.3 mM N-acetyl-
glucosamine were added [82]. All components except for the latter two were dissolved
together, sterilized by filtration through a 0.22 μm membrane, and stored for up to 2 weeks;
FeSO4.7H2O and N-acetyl-glucosamine solutions were prepared fresh each time or stored
at −20˚C, respectively, and added to SCFM on the day of use. For SCFM agar, a 2× solution of
the medium components was prepared and added to a separately autoclaved 3% molten agar
solution, for a final concentration of 1× SCFM and 1.5% agar.
Antibiotics were prepared in concentrated stock solutions (100× or greater) and stored at
−20˚C. Ciprofloxacin was dissolved in 0.1 M or 20 mM HCl, while levofloxacin, gentamicin,
tobramycin, and colistin were dissolved in sterile deionized water. PAβN dihydrochloride
(MedChemExpress, Monmouth Junction, New Jersey, USA) was dissolved in sterile deionized
water (50 mg/mL). PYO was synthesized and purified as previously described [83,84] and dis-
solved in 20 mM HCl to make 10 mM stock solutions. Experiments involving exogenous PYO
always included negative controls to which an equivalent volume of 20 mM HCl was added. In
addition, MH agar plates were buffered to pH 7 with 10 mM 4-morpholinepropanesulfonic
acid (MOPS) to avoid any pH changes upon addition of PYO or HCl; all other media used
with exogenous PYO were already inherently buffered. Incubations were always done at 37˚C,
with shaking for liquid cultures (250 rpm), unless mentioned otherwise.
Strain construction
In this study, we use PA14 as an abbreviation for UCBPP-PA14. P. aeruginosa PA14 was used
for all experiments unless otherwise noted. For a full list of strains made in this study, see S5
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Table. Three types of strains were made in different P. aeruginosa PA14 backgrounds: (i)
unmarked deletions, used for Tn-seq validation experiments; (ii) fluorescent strains for time-
lapse microscopy experiments; and (iii) strains overexpressing one of the following 3 systems:
mexGHI-opmD, ahpB, and katB. Established protocols were used for all these procedures [85].
Briefly, for unmarked deletions, approximately 1-kb fragments immediately upstream and
downstream of the target locus were cloned using Gibson assembly into the pMQ30 suicide
vector [86,87]. Fragments amplified from P. aeruginosa PA14 genomic DNA (gDNA) and
cleaned up using the Monarch PCR Purification kit (New England Biolabs, Ipswich, Massa-
chusetts, USA) were used for Gibson assembly together with pMQ30 cut with SacI and Hin-
dIII. The assembled construct was then transformed into E. coliDH10B, with transformants
being selected in LB with 20 μg/mL gentamicin. All correctly assembled plasmids were identi-
fied by colony PCR and verified by Sanger sequencing (Laragen, Culver City, California,
USA). Next, for the insertion of the constructs into P. aeruginosa PA14 genome, triparental
conjugation was performed following Choi and Schweizer [88]. All unmarked deletions were
done in the P. aeruginosa PA14 Δphz background (both phzA-G1 and phzA-G2 operons are
deleted in this strain [13]), allowing clean experiments by addition of exogenous phenazines.
Merodiploids containing the construct integrated into their genomes were selected on VBMM
medium (3 g/L trisodium citrate, 2 g/L citric acid, 10 g/L K2HPO4, 3.5 g/L NaNH4PO4�4H2O,
1 mM MgSO4, 100 μM CaCL2, pH 7) with 100 μg/mL gentamicin following Choi and Schwei-
zer [88]. Finally, merodiploids were then plated on LB lacking NaCl and containing 10%
sucrose to select for colonies resulting from homologous recombination. Colonies missing the
target locus (unmarked deletions) were identified by PCR. For all primers used, see S5 Table.
Fluorescent strains used in time-lapse microscopy were made using previously published
plasmids [85,89]. Constructs containing GFP and mApple florescent proteins under the con-
trol of the ribosomal rpsG gene were inserted in the attTn7 site of P. aeruginosa PA14 Δphz
chromosome by tetraparental conjugation, followed with selection on VBMM with 100 μg/mL
gentamicin [88].
Finally, overexpressing strains were made as previously described [85]. The previously
made overexpression construct (pUC18T-miniTn7T-GmR vector containing the arabinose-
inducible promoter Para [85]) and the 3 different targets (mexGHI-opmD, ahpB, and katB)
were all amplified by PCR. Next, using Gibson assembly, the targets were cloned downstream
of Para in the pUC18T-miniTn7T-GmR vector, resulting in the 3 different overexpression con-
structs: Para:mexGHI-opmD, Para:ahpB, and Para:katB. The final constructs were introduced
into the attTn7 of the P. aeruginosa PA14 Δphz background strain by tetraparental conjugation
[88].
Transposon sequencing (Tn-seq) experiment
The Tn-seq experiment was performed following the design presented in Fig 1A. Two aliquots
of the P. aeruginosa PA14 transposon library previously prepared [89] were thawed on ice for
15 minutes, diluted to a starting optical density (OD500) of 0.05 in 50 mL of SMM, and grown
aerobically under shaking conditions (250 rpm) at 37˚C for approximately 4 to 5 generations
to an OD500 of 0.8–1. These growing conditions were used for all the stages of the experiment.
After growth in SMM, each aliquot was considered an independent replicate. Cells from each
replicate were pelleted, washed, and resuspended (5 mL in 18 × 150 mm glass tubes, OD500 =
2) in minimal phosphate buffer (MPB; 50 mM KH2PO4/K2HPO4[pH 7], 42.8 mM NaCl) with
and without 100 μM PYO. Cells were then incubated for 26 hours under shaking conditions at
37˚C. Therefore, the experiment consisted of 4 different samples that were later sequenced: (i)
“R1 No PYO”; (ii) “R1 + PYO”; (iii) “R2 No PYO”; and (iv) “R2 + PYO.” After the incubation,
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cultures from all treatments were pelleted, washed again to remove PYO, and resuspended in
fresh SMM. Immediately, an aliquot of each sample was diluted to a starting OD500 of approxi-
mately 0.05 in 25 mL SMM, followed by outgrowth for approximately 4 to 5 generations to an
OD500 of 0.8–1. After outgrowth, 2.5 mL of each sample was pelleted and stored at −80˚C.
gDNA was extracted from the pelleted samples using the DNeasy Blood & Tissue kit (Qia-
gen, Valencia, California, USA). All the steps for sequencing library preparation followed
exactly the protocol used by Basta and colleagues [89], including (i) DNA shearing by sonica-
tion (to produce 200- to 500-bp fragments); (ii) end repair; (iii) addition of poly(C) tail; and
(iv) enrichment of transposon–genome junctions and addition of adapter for Illumina
sequencing by PCR [89,90]. The resulting amplified DNA samples were sequenced using
100-bp single-end reads on the Illumina HiSeq 2500 platform at the Millard and Muriel Jacobs
Genetics and Genomics Laboratory at Caltech. Data analysis also followed Basta and col-
leagues [89]. In summary, sequences were mapped to the P. aeruginosaUCBPP-PA14 genome
sequence using Bowtie 2 [91] and were analyzed in MATLAB using the ARTIST Tn-seq analy-
sis pipeline [92], with nonoverlapping windows of 100 bp across the genome [89,92]. Using
the Mann–Whitney U statistical test, the total reads mapping for each gene in the “+PYO”
samples were compared to the corresponding reads in the “No PYO” control for each replicate
independently [89,92]. Next, the read ratio for each replicate was calculated within ARTIST
for each gene and then log2 transformed. Finally, the p-values for both replicates were com-
bined using the Fisher combined probability test as done in Basta and colleagues [89], and the
average of the log2 ratios of the 2 replicates are also shown. For the log2 ratios and p-values for
all PA14 genes, see S1 Table. For heatmaps shown in Fig 1A, the average log2 ratios (fitness)
for the selected genes were plotted using the geom_tile() function from the ggplot2 package in
R [93,94].
Tn-seq datasets correlation analysis
To compare the results of this Tn-seq analysis with a previously published study [24] analyzing
fitness determinants for survival during ciprofloxacin treatment in the P. aeruginosa PAO1
strain background (Fig 1E, S1 Table), the data from that study’s supplemental S1 Table were
used. The normalized average ratio of reads in the treated sample compared to reads in the
input sample for each gene (geometric mean of 3 replicates) was log2 transformed for compari-
son to the Tn-seq data described above. The list of genes was filtered to include only genes for
which ratios were reported in both our PYO Tn-seq experiment and the ciprofloxacin Tn-seq
study and for which there are clear orthologs in both strains (n = 4,209 genes). Orthologs were
determined using the “pseudomonas.com” database [95].
Tn-seq validation experiments
To validate the Tn-seq results (Fig 1C), experiments were performed by comparing the sur-
vival of 4 different mutants (ΔphzΔackAΔpta, ΔphzΔlptA, ΔphzΔmexS, and ΔphzΔdctBD) to
the survival of the Δphz strain upon exposure to PYO. The experimental design was very simi-
lar to the one used in for the Tn-seq, with minor adaptations. An overnight culture (5 mL) of
each strain was grown in SMM (40 mM succinate) from LB plates. Cells were washed and
resuspended at an OD500 of 0.1 (or 0.25 for ΔphzΔdctBD) in the same medium to start the new
cultures (5 mL), which were grown to OD500 approximately 0.8–1, pelleted, washed, and resus-
pended in the same minimal medium without succinate (no carbon source) at OD500 of 1. For
each strain, the culture was split across 8 to 12 wells (150 μL cultures) in a 96-well plate, with
100 μM PYO added to half of the cultures. Moreover, 70 μL of mineral oil was added to the top
of the wells to prevent evaporation. PI at 5 μM was also added to the cultures to monitor cell
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death [16]. The plate was then moved to a BioTek Synergy 4 plate reader (BioTek, Winooski,
Vermont, USA) and incubated under shaking conditions at 37˚C for 24 hours. After incuba-
tion, cultures were serially diluted in buffer and plated for CFUs on LB agar, and survival in
the presence of PYO was compared to the no-PYO control. Plates were incubated at room
temperature (RT), and CFUs were counted after 36 to 48 hours. In this study, a stereoscope
was always used to count the CFUs. Survival levels were calculated for each mutant (i.e., for
each replicate, the % survival for “+PYO” was calculated based on CFUs for “No PYO”). Then,
the survival levels for each mutant were normalized by the survival levels of the Δphz parent
strain (i.e., % survival for “+PYO” for each mutant was divided by the average % survival for
“+PYO” of the Δphz strain); these “fitness” values were log2 transformed for plotting.
PYO tolerance with efflux inhibitor
Survival assays with efflux inhibition were performed to test the importance of efflux systems
in P. aeruginosa for tolerance against PYO toxicity. From a Δphz overnight culture pre-grown
in SMM (20 mM succinate), a new 7-mL culture was started in fresh SMM at an OD500 of 0.05
and was incubated for around 10 hours (enough to reach stationary phase). Cells were then
pelleted, washed, and resuspended in MPB at an OD500 of 1 (10 mL of culture was prepared).
The culture was then split into 4 different treatments: (i) no PYO, no PAβN; (ii) 100 μM PYO,
no PAβN; (iii) no PYO, with PAβN (50 μg/mL); and (iv) 100 μM PYO, with PAβN. Each of the
treatments were split across 12 wells containing 150 μL of culture + 70 μL of mineral oil in a
96-well plate. The plate was incubated at 37˚C under shaking conditions using a BioTek Syn-
ergy 4 plate reader. Samples were serially diluted in MPB and plated for CFUs on LB agar after
12, 24, and 48 hours. Survival for treatments containing PYO was calculated based on the
CFUs counted for the negative control without PYO (Fig 1D). At each time point, 4 wells were
sampled, with each well considered an independent replicate. The experiment was repeated
twice with similar results.
Antibiotic tolerance experiments using P. aeruginosa
Tolerance assay for WT, Δphz, and Δphz + PYO. For most antibiotic tolerance assays
(except for tolerance using cells harvested during log phase, see below), the experimental
design shown in S4A Fig was followed. WT and Δphz cells were grown from a plate into over-
night cultures in GMM with 20 mM glucose. Next, WT and Δphz cells were pelleted, washed,
and resuspended at an OD500 of 0.05 in 4 independent new cultures (replicates) in GMM (10
mM glucose) per treatment. Three treatments were prepared: WT, Δphz (no PYO), and Δphz
+ 100 μM PYO, with 4 independent biological replicates for each. Each of the 4 individual cul-
tures (replicates) were incubated for around 20 hours, reaching stationary phase, in 7-mL cul-
tures (18 × 150 mm glass tubes). Each individual culture (replicate) was then split into a
negative control (no antibiotic) or antibiotic treatment (2 mL of culture per each treatment,
using plastic Falcon tubes, VWR, Cat. No. 352059, Radnor, Pennsylvania, USA). After addition
of the antibiotic from concentrated stocks, cultures were incubated for 4 hours, serially diluted
in MPB and then plated for CFUs on LB agar. Unless stated otherwise, cells were not washed
before plating. We observed that washing the cells did not make any difference in the outcome
of the experiments. In addition, washing was not feasible for the tolerance assays using smaller
volumes (i.e., in 96-well plates). The only 2 experiments where washing was performed are
described below (“Tolerance assay with PAβN” and “Tolerance assay to measure the lag in
CFUs appearance”). In these cases, cells were washed because (i) the ciprofloxacin concentra-
tions were higher (10 μg/mL) and more likely to affect P. aeruginosa cells on the plate; and (ii)
for the case of the PAβN experiment, we wanted to avoid having cells be in contact with the
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inhibitor while growing on the plate. Antibiotics were used at the concentrations mentioned
in figure legends. Plates were incubated at RT, and CFUs were counted after 36 to 48 hours.
Plates were always checked again after 7 days to count any late-arising CFUs. Importantly, for
all tolerance experiments performed in this study (including this and all experiments described
below), each experiment was repeated at least twice on different days, with similar results.
The same protocol was followed for the experiment testing different concentrations of PYO
(Fig 2H) and for the experiment testing how PYO impacts tolerance of different P. aeruginosa
mutants with partial resistance to ciprofloxacin (CipR-21, 25, 33, and 40; S7E Fig). For the
experiment testing tolerance after exposure to different phenazines (Fig 2E), all the phenazines
were dissolved in a common solvent (DMSO), which was used as the negative control; these
experiments were performed in a Δphz� mutant lacking not only the phzA-G1 and phzA-G2
operons but also all phenazine modification genes, to prevent the transformation of PCA into
the other phenazines (see S5 Table). For experiments performed in SCFM (Fig 2D), the same
experimental design was followed, with the exception that SCFM was used instead of GMM.
Tolerance assay for strains with arabinose-inducible constructs. For these experiments
(Fig 2I, S6B Fig), the 20-hour cultures of each strain (Δphz Para:mexGHI-opmD, Δphz Para:
ahpB, and Δphz Para:katB) were grown with and without 20 mM arabinose for induction of the
controlled systems and then exposed to ciprofloxacin the same way described above. To rule
out any nonspecific interference of the inducer, negative controls with and without 20 mM
arabinose using the parent Δphz strain (without the insertions in the attTn7 site) were also
done. Adding arabinose to the Δphz strain did not impact tolerance levels (S6 Fig).
Tolerance assay with PAβN. Experiments using the efflux inhibitor PAβN (S4G Fig)
were also performed similarly to the way as described above. The only differences were that
after the 20 hours incubation and before the addition of the antibiotic, PAβN was added to the
cultures at a final concentration of 50 μg/mL. Cultures were incubated for 15 minutes and
then ciprofloxacin was added, followed by a 4-hour incubation. For these experiments, instead
of plating cells directly on LB, 1 mL of culture of each replicate/treatment was pelleted (12,500
rpm for 2 minutes), washed in MPB for removal of ciprofloxacin and PAβN, and only then
serially diluted in MPB and plated on LB for CFU counting.
Tolerance assay to measure the lag in CFUs appearance. This experiment (S4F Fig) fol-
lowed the same general protocol described above (using 10 μg/mL of ciprofloxacin). The dif-
ference was that the reported CFUs were counted after incubation of LB plates for 2 days and 7
days, whereas otherwise only the final counts from the seventh day were reported. This was
done to quantify lag in the CFUs’ growth under the studied conditions. Similar to the tolerance
assays with PAβN and ciprofloxacin described above, cells were pelleted and washed before
plating on LB for CFU counting.
Tolerance assay for cells harvested during log phase. Δphz cells were grown in overnight
cultures in GMM (20 mM glucose). Next, cells were pelleted, washed, and resuspended into 2
new cultures, one with PYO (100 μM) and one without PYO, at an OD500 of 0.05 in GMM (10
mM glucose, 7-mL cultures). Cultures were grown until OD500 = 0.5 (around 5 to 6 hours).
Cells were then washed and resuspended in the same medium at an OD500 of 0.5, but without
the nitrogen source (i.e., no NH4Cl). PYO was re-added after washes to the culture that was
pre-grown with PYO. The cultures, one with and one without PYO, were then split into differ-
ent treatments: negative control (no antibiotic), ciprofloxacin (0.5 μg/mL), levofloxacin (1 μg/
mL), gentamicin (16 μg/mL), and tobramycin (4 μg/mL). Then, they were all transferred to
wells in a 96-well plate (3 to 4 wells per treatment, with each well being considered an indepen-
dent replicate). Cultures within wells contained 150 μL with an additional 70 μL of mineral oil
on top to prevent evaporation. The depletion of nitrogen prevented growth in the negative
control, which limited overestimation of the antibiotic killing effect (because survival rates
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were calculated relative to the negative control). The plates were incubated for 4 hours at 37˚C
under shaking conditions (175 rpm) using a benchtop incubator (VWR incubator orbital
shaker). The 96-well plate was kept inside an airtight plastic container with several wet paper
towels to maintain high humidity attached to the shaker. After incubation, cells were serially
diluted and plated on LB agar for CFU counting (S4B Fig). A similar experiment was also per-
formed with the strains containing arabinose-inducible constructs (Δphz Para:mexGHI-opmD,
Δphz Para:ahpB, and Δphz Para:katB) and the Δphz background control (S6A Fig), for which tol-
erance to ciprofloxacin (0.5 μg/mL) was tested. The experiment followed the same protocol
described above, with the difference that, instead of presence or absence of PYO, strains were
incubated in the presence or absence of 20 mM arabinose.
Time-lapse microscopy experiment and quantification
Fluorescently tagged strains of WT or Δphz were grown in GMM, and tolerance experiments
were performed as shown in S4D Fig using ciprofloxacin (10 μg/mL). After the 4-hour incuba-
tion with the antibiotic, cells were washed and resuspended in GMM. The 2 different strains
were then mixed and placed on an agarose pad containing GMM (no ciprofloxacin or PYO
was added to the pad). Agarose pads were placed into a PELCO Clear Wall Glass Bottom Dish
(Cat. No. 14023–20), and the dish was used for imaging within the microscope incubation
chamber. Outgrowth was visualized using a Nikon Ti2E microscope with Perfect Focus System
4 (Nikon Instruments, Melville, New York, USA). Incubation proceeded for 12.5 to 15 hours
at 37˚C, with imaging every 15 minutes in bright field (phase contrast) and green and red fluo-
rescence channels (50-ms exposure with 470-nm LED lamp and a green-FITC filter [ex = 465
to 495 nm, em = 515 to 555 nm] for GFP; 50-ms exposure with 555-nm LED lamp and a quad
band filter [red ex = 543 to 566 nm, red em = 580 to 611 nm] for mApple).
For image analysis, a Fiji macro was used. Briefly, fluorescent channels (GFP/mApple) of the
first and last time points were segmented using the “Auto Threshold” function and “Default” set-
ting. The area of the segmented cells was then recorded using the “Analyze Particles” function in
Fiji [96]. This allowed for quantification of the total area covered by cells within each channel,
with each field of view being processed separately. After that, for each field of view, the total area
covered by WT cells (or Δphz + 100 μM PYO, depending on the experiment) was divided by the
area covered by Δphz cells to obtain the relative “growth area ratios”. This was done for first and
last time points. Three experiments were performed, with different fluorescent protein/strain
combinations: (i) WT::mApple/Δphz::GFP (n = 13 fields of view, Fig 2F and 2G, S1 Movie); (ii)
Δphz::GFP+PYO /Δphz::mApple (n = 19, Fig 2G); and (iii) WT::GFP/Δphz::mApple (n = 16, S4E
Fig). GFP/mApple were controlled by the rpsG promoter for all of the strains (S5 Table).
RNA extraction and quantitative reverse transcriptase PCR (qRT-PCR)
Experiment 1—Measurement of PYO-induced gene expression. Six different treatments
were prepared for this qRT-PCR experiment: (i) WT PA14; (ii) Δphz; (iii) Δphz + 1 μM PYO;
(iv) Δphz + 10 μM PYO; (v) Δphz + 100 μM PYO; and (vi) Δphz + 200 μM PYO. Cultures of
WT or Δphz were grown overnight in GMM (20 mM glucose), then cells were washed and
resuspended at an OD500 of 0.05 (3 replicates) in fresh GMM (5 mL in culture tubes). Different
concentrations of PYO were added to Δphz cultures as mentioned, and all cultures were incu-
bated for around 8.5 hours (until early stationary phase). This was enough time for WT to
make PYO (around 50 to 70 μM, measured by absorbance at OD691 [97]). After incubation,
cells were pelleted, immediately frozen using liquid nitrogen, and stored at −80˚C.
Experiment 2—Measuring arabinose induction of mexGHI-opmD, ahpB, and katB.
Eight different treatments were prepared for this qRT-PCR experiment, in which each of the 4
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tested strains (Δphz, Δphz Para:mexGHI-opmD, Δphz Para:ahpB, and Δphz Para:katB) were incu-
bated with and without 20 mM arabinose for artificial induction of the constructs. Cultures of
the 4 strains were grown overnight in GMM (20 mM glucose), then cells were washed and
resuspended at an OD500 of 0.05 (3 replicates) in the same medium (5 mL in culture tubes),
with and without 20 mM arabinose (for conditions without arabinose, the respective amount
of water was added). Cultures were incubated for around 8.5 hours, then pelleted, immediately
frozen using liquid nitrogen, and stored at −80˚C.
For RNA extraction, previously published protocols were followed [16,85]. Briefly, samples
were thawed on ice for 10 minutes and resuspended in 215 μL of TE buffer (30 mM Tris.Cl, 1
mM EDTA, pH 8.0) containing 15 mg/mL of lysozyme + 15 μL of proteinase K solution (20
mg/mL, Qiagen) and then incubated for 8 to 10 minutes. For lysis steps and RNA extraction,
the RNeasy kit (Qiagen) was used. Samples were then treated with TURBO DNA-free kit (Invi-
trogen, Waltham, Massachusetts, USA) for removal of any contaminant gDNA. Next, cDNA
was synthesized using iScript cDNA Synthesis kit (Bio-Rad, Hercules, California, USA) (1 μg
of total RNA was used). For these kits, the manufacturer’s instructions were followed.
qRT-PCR reactions were performed using iTaq Universal SYBR Green Supermix (Bio-Rad) in
20 μL reactions using a 7500 Fast Real-Time PCR System machine (Applied Biosystems, Wal-
tham, Massachusetts, USA) following published protocols [16]. Standard curves for each
primer pair were prepared using P. aeruginosa gDNA and were used for calculation of cDNA
for each gene studied. The housekeeping gene oprI was used as a control gene for normaliza-
tions [85].
Data showing total oprI-normalized cDNA levels (i.e., cDNA measured for a certain gene
in a certain sample, divided by the respective cDNA measured for oprI in the same sample)
and the log2 fold change in expression are shown in Fig 2B and S1–S3 and S5 Figs. Fold
changes were calculated relative to the mean value for Δphz samples without added PYO (Fig
2B, S1B and S3 Figs) or the mean value of samples from the same strain without added arabi-
nose (S5B Fig). cDNA values for replicates within each efflux gene/treatment (shown in S2
Fig) were averaged and used with the geom_tile() function in R [93,94] for generation of the
heatmap shown in Fig 2B.
Stenotrophomonas and Burkholderia growth curves and antibiotic
tolerance assays
S.maltophilia ATCC 13637, B. cepacia ATCC 25416, B. cenocepacia AU42085, B.multivorans
AU42096 (B.multivorans 1), and B. gladioli AU42104 were used in the growth experiments
shown in Fig 5A (for strain details, see S5 Table). Each strain was grown overnight in GMM
(20 mM glucose, 5 mL culture tubes) supplemented with 1× MEM AA (MilliporeSigma, Cat.
No. M5550, Burlington, Massachusetts, USA). Cells were pelleted, washed, and resuspended in
new cultures at an OD500 of 0.05 in the same medium. Cultures were then split, different con-
centrations of PYO were added (0, 10, 50, or 100 μM for S.maltophilia; 0, 10, or 100 μM for all
others), and moved to a 96-well plate (4 to 6 wells per treatment, with each well being consid-
ered an independent replicate). Cultures within wells contained 150 μL with an additional
70 μL of mineral oil on top to prevent evaporation. The plates were incubated at 37˚C under
shaking conditions using a BioTek Synergy 4 plate reader with OD500 measurements every 15
minutes for 24 hours to measure growth. Assays for tolerance to ciprofloxacin with or without
exogenous PYO were performed for S.maltophilia (sensitive to PYO) and for 4 Burkholderia
strains (all resistant to PYO): B. cepacia, B. cenocepacia, B.multivorans 1, and B.multivorans
AU18358 (B.multivorans 4). The experiments followed exactly what was done for P. aerugi-
nosa (S4A Fig), except that cultures were grown in GMM + AA, and are shown in Fig 4B–4E.
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Finally, a tolerance assay in SCFM with and without PYO was performed for B.multivorans 1
(Fig 5H) and followed what was described for the SCFM experiments in P. aeruginosa (with
the only difference being the ciprofloxacin concentrations, always mentioned in the legends).
Coculture antibiotic tolerance experiments
To test how PYO produced by P. aeruginosa impacts tolerance to ciprofloxacin in other spe-
cies, coculture experiments were performed using membrane-separated 12-well tissue plate
cultures containing 0.1 μm pore PET membranes (VWR Cat. No. 10769–226). Briefly, over-
night cultures of the P. aeruginosa strain (WT/Δphz PA14 or PA 76–11) and the respective
other species tested (S.maltophilia, B. cepacia, B. cenocepacia, or B.multivorans 1) were pre-
pared in GMM (20 mM glucose) + AA. Cells were pelleted, washed, and resuspended to differ-
ent ODs as follows: (i) for any P. aeruginosa–Burkholderia assay, P. aeruginosa starting OD500
= 0.05 and Burkholderia starting OD500 = 0.025; and (ii) for the P. aeruginosa–S.maltophilia
assay, P. aeruginosa starting OD500 = 0.01 and S.maltophilia starting OD500 = 0.1. P. aerugi-
nosa was cultured in the bottom part of the well (600 μL), while the other species was cultured
in the upper part of the well (100 μL), as shown in Fig 5C. B. cepacia and S.maltophilia were
cultured either with WT or Δphz P. aeruginosa PA14 (with and without 100 μM PYO exoge-
nously added).
B. cenocepacia and B.multivorans 1 were cultured either with PA 76–11 (a P. aeruginosa
strain isolated from CF sputum that produced 50 to 100 μM PYO in these assays) or alone in
the presence or absence of 100 μM PYO. For cases where Burkholderia was grown alone, the
strain tested was grown in both the bottom and top parts of the membrane-separated wells. In
all experiments, cocultures were grown for around 20 hours at 37˚C under shaking conditions
(175 rpm) using a benchtop incubator, followed by addition of ciprofloxacin (concentrations
were either 1 or 10 μg/mL, as specified in the figure legends) and incubation for 4 hours. The
membrane-separated plates were kept inside an airtight plastic container with several wet
paper towels to maintain high humidity attached to the shaker. For every coculture combina-
tion in the membrane-separated plate, 3 wells were used as a negative control (no antibiotic),
and 3 wells were used for ciprofloxacin treatment; each well was considered an independent
replicate. After incubation with ciprofloxacin, cells were serially diluted in MPB and plated for
CFUs on LB. In most cases, only Burkholderia cells were plated (Fig 5F). However, to test if
our P. aeruginosaWT strain was still more tolerant than the Δphz strain when both were
grown in the presence of a Burkholderia species, we performed an experiment with P. aerugi-
nosa PA14 and B.multivorans 1 where we treated the cocultures with ciprofloxacin 1 μg/mL
and plated P. aeruginosa (Fig 5G). Finally, we also performed a coculture experiment in SCFM
(P. aeruginosa PA14 WT/Δphz with B.multivorans 1) to test if PYO produced by PA14 WT
increases tolerance in Burkholderia in this medium (Fig 5I). This experiment in SCFM fol-
lowed the same overall experimental design used before, except for using SCFM instead of
GMM in all steps.
Determination of minimum inhibitory concentrations
The antibiotic concentrations used for selecting de novo antibiotic-resistant mutants in the
fluctuation tests were chosen based on the results of a modified agar dilution MIC assay. Over-
night cultures were grown for each strain in GMM (with 10 mM glucose) or GMM (10 mM
glucose) + AA, respectively, then diluted to an OD500 of 0.5, from which 3 μL was spotted onto
MH agar containing a 2-fold dilution series of the antibiotic. After the spots dried, the antibi-
otic plates were incubated upside down for 48 hours at 37˚C before assessing the spots for
growth. We considered the MIC to be the first concentration at which there was neither a lawn
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of background growth nor dozens of overlapping colonies visible without magnification. We
generally used 2 times this MIC as the selection condition for fluctuation tests; for P. aerugi-
nosa, this corresponded to the EUCAST [27] resistance breakpoints for ciprofloxacin and levo-
floxacin, while our chosen concentrations of gentamicin and tobramycin were 2-fold higher
than the EUCAST breakpoints [32]. EUCAST breakpoints are not available for Stenotropho-
monas spp. or the B. cepacia complex. The appropriateness of the selection condition was addi-
tionally verified by performing a fluctuation test, as described below, and choosing the
antibiotic concentration that reliably yielded a countable number of colonies (0 to several
dozen, with at least several nonzero counts per 44 parallel cultures) in each well.
Ciprofloxacin MICs for parent strains and isolated mutants from the fluctuation tests were
determined according to standard clinical methods for broth microdilution assays [27]. In
brief, cells from either overnight cultures in MH broth or fresh streaks on LB agar (14 to 16
hours old) were resuspended to a density of 3 to 7 × 105 CFUs/mL in a 2-fold dilution series of
ciprofloxacin in MH broth, with or without 100 μM PYO. The dilution series were set up in a
final volume of 100 μL per well in 96-well microtiter plates, with appropriate no-antibiotic and
cell-free controls. Three biological replicates (independent overnight cultures or cell suspen-
sions) were prepared for each tested strain. Following inoculation, the microtiter plates were
sealed with a plastic film to prevent evaporation and incubated in a single layer at 37˚C, with-
out shaking. The wells were assessed for growth (turbidity) visible to the naked eye after 18
hours of incubation.
Fluctuation tests, calculation of mutation rates, and model fitting
For all tested strains and conditions, fluctuation tests were performed by inoculating 200-μL
cultures in parallel in a flat-bottomed 96-well plate. All reported fluctuation test data for P. aer-
uginosa are from experiments using the Δphz strain. We also performed fluctuation tests using
the P. aeruginosa PA14 WT strain and performed phenotypic and genotypic characterization
of partially resistant mutants detected in those experiments (see below); however, the effect of
PYO on apparent mutation rates in WT was difficult to interpret due to inconsistent PYO pro-
duction in the 96-well plates. For cultures that were grown with PYO (or arabinose in the case
of strains with arabinose-inducible constructs), the PYO (or 20 mM arabinose) was added to
the medium before inoculation. The cultures were inoculated with a 10−6 dilution of a single
overnight culture (representing a biological replicate) that had first been diluted to a standard
OD500 of 1.0, corresponding to an initial cell density of approximately 2,000 to 2,500 CFUs/mL
(400 to 500 cells/culture). Each treatment condition consisted of 44 such parallel cultures.
The 96-well plates were placed inside an airtight plastic container with several wet paper
towels to maintain high humidity, then incubated at 37˚C with shaking at 250 rpm. For plating
during log phase, the cultures were incubated until reaching approximately half-maximal den-
sity (OD500 of 0.4 to 0.7 for P. aeruginosa in GMM with 10 mM glucose or 0.9 to 1.2 for P. aer-
uginosa in SCFM or B.multivorans in GMM + AA). For plating during stationary phase, the
cultures were incubated for 24 hours. The cultures were then plated by spotting 40 to 50 μL
per culture into single wells of 24-well plates (for any given experiment, the same volume was
spotted for all parallel cultures); each well contained 1 mL of MH agar or SFCM agar plus an
antibiotic, with or without 100 μM PYO (or 20 mM arabinose for strains with arabinose-
inducible constructs). In the case of B.multivorans cultures that were spotted onto antibiotic
plates containing 100 μM PYO, the cultures were first diluted 1:10 (if not pretreated with
100 μM PYO) or 1:100 (if pretreated with 100 μM PYO).
At the same time as plating onto the antibiotic plates, 6 representative cultures from each
treatment were serially diluted and plated on LB agar plates to assess total CFUs. The antibiotic
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plates were incubated upside down, in stacks of no more than 8, at 37˚C for 16 to 24 hours for
P. aeruginosa (except for gentamicin plates, which were incubated for 40 to 48 hours) or 40 to
48 hours for B.multivorans. Subsequently, colonies were counted under a stereoscope at the
highest magnification for which the field of view still encompassed an entire well; occasionally,
a well contained too many colonies to count (a so-called “jackpot” culture [98]), in which case
that culture was discarded from further analysis. The LB agar plates for total CFU counts were
incubated for 30 to 36 hours at RT before counting colonies at the same magnification.
Mutation rates reported in the figures were calculated using the function newton.LD.plat-
ing from the R package rSalvador [99] to estimatem, the expected number of mutations per
culture. This is a maximum likelihood-based method for inferring mutation rates from fluctu-
ation test colony counts, based on the classic LD distribution with a correction to account for
the effects of partial plating (i.e., plating a portion of each culture rather than the total volume)
[99]. We chose this method because it has been shown to be the most accurate estimator ofm
when partial plating is involved [99,100]. To get μapp (apparent mutation rate per generation)
fromm, we dividedm by the total number of cells per parallel culture [99], as estimated from
the mean number of CFUs counted for the 6 representative cultures.
To compare the fits of different formulations of the LD distribution to our data, we gener-
ated theoretical cumulative distributions using the parameter values estimated for our data.
Specifically, for the Hamon and Ycart version of the LD model [44], we estimatedm and w
(relative fitness of mutants compared to the parent strain in the nonselective pre-plating liquid
growth medium) using the function GF.est from the R script available at http://ljk.imag.fr/
membres/Bernard.Ycart/LD/ (version 1.0; note that in the script,m is called alpha and 1/w is
called rho); then, we used the function pLD from the same script to generate the theoretical
distribution. For the mixed LD–Poisson and basic LD models, we wrote and used an R transla-
tion of the MATLAB code written by Lang and colleagues [45]; the original code is available at
https://github.com/AWMurrayLab/FluctuationTest_GregLang. The basic LD model used by
Lang and colleagues [45] is equivalent to that available in the rSalvador package (using the
function newton.LD), except without the correction for partial plating; the latter is only impor-
tant when using the estimate ofm to infer the mutation rate, not when comparing the fits of
different models to the empirical cumulative distribution of the raw colony counts.
Plots of the empirical cumulative distributions of our data against the theoretical models
showed that the Hamon and Ycart model was a visually good fit in all cases (see Figs 4B and
6C and S9 Fig for examples). To further assess goodness of fit of the Hamon and Ycart model,
we performed Pearson chi-squared test in R after binning the data and theoretical distribution
such that the expected number of cultures in each bin of mutant counts was at least 5 [101]. To
compare the goodness of fit of the Hamon and Ycart model to the basic LD model, we calcu-
lated the negative log likelihood for each model and performed the likelihood ratio test. To
compare the Hamon and Ycart model to the mixed LD–Poisson model, we simply compared
the negative log likelihoods (smaller values indicate a better fit); the likelihood ratio test was
not applicable as these 2 models contain the same number of parameters. Note that although
the Hamon and Ycart (or in some cases, LD–Poisson) models were often better fits than the
basic LD model, we still used the basic LD model for statistical comparison of mutation rates
between conditions, because an accurate method to account for partial plating has not yet
been developed for the cases of post-plating mutations or differential fitness between mutants
and parent strains [99]. Nevertheless, similar patterns in mutation rates were observed when
using an older method of accounting for partial plating to derive μapp from the Hamon and
Ycart model [102]; the Pearson correlation coefficient was 0.98 for mutation rates calculated
with the newton.LD.plating function in rSalvador versus the partial plating–corrected Hamon
and Ycart method (S3 Table). We also separately performed nonparametric statistical analysis
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of the raw mutant frequencies (i.e., mutant colony counts divided by the number of cells per
parallel culture), as such analysis is agnostic to any assumptions about the biological processes
underlying the data. The statistical significance of this analysis generally corresponded with
the statistical significance of a likelihood ratio test based on the newton.LD.plating model of
mutation rates, indicating that the effects of PYO were robust to different mathematical
approaches to analyzing the fluctuation test data (S2 Table).
Characterization of antibiotic resistance phenotypes
We defined putative ciprofloxacin-resistant mutants as “enriched” by PYO in the fluctuation
tests if colonies with a given morphology were at least 2 times more numerous on the PYO-
containing ciprofloxacin plate than the respective non-PYO-containing ciprofloxacin plate
derived from the same 200-μL culture. These putative mutants could be either from the PYO
pretreated or non-PYO pretreated branches of the fluctuation test. Putative mutants that were
seemingly enriched by PYO were restreaked for purity on PYO-containing agar plates at the
same ciprofloxacin concentration on which they were selected in the fluctuation test (0.5 μg/
mL for PA and 8 μg/mL for B.multivorans). Putative mutants that were not enriched by PYO
were restreaked on ciprofloxacin agar plates without PYO. Frozen stocks of each restreaked,
visually pure isolate were prepared by inoculating cultures with single colonies in 5 mL of liq-
uid LB, incubating to stationary phase, mixing 1:1 with 50% glycerol, and storing at −80˚C.
The levels of ciprofloxacin resistance of selected isolates, as well as the parent strains, were
assessed using a CFU recovery assay as follows. For each isolate, four 5 mL cultures in GMM
(for P. aeruginosa) or GMM + AA (for B.multivorans) were inoculated directly from the fro-
zen stock to minimize the number of generations in which secondary mutations could be
acquired. The cultures were grown to stationary phase overnight, then subcultured to an
OD500 of 0.05 in 5 mL of fresh GMM (for P. aeruginosa) or GMM + AA (for B.multivorans),
with or without 100 μM PYO. The new cultures were grown to mid-log phase, then serially
diluted in GMM or GMM + AA (+/− 100 μM PYO as appropriate) and plated for CFUs (10 μL
per dilution step) on (1) plain MH agar; (2) MH agar + ciprofloxacin; and (3) MH agar + cipro-
floxacin + 100 μM PYO. The lowest plated dilution was 10−1, making the limit of detection
approximately 1,000 CFUs/mL.
Identification of mutations by whole-genome sequencing
gDNA was isolated from selected putative mutants and the parent strains using the DNeasy
Blood & Tissue kit (Qiagen). Library preparation and 2 × 150 bp paired-end Illumina sequenc-
ing was performed by the Microbial Genome Sequencing Center (Pittsburgh, Pennsylvania,
USA), with a minimum of 300-Mb sequencing output per sample (approximately 50 × cover-
age). Forward and reverse sequencing reads were concatenated into a single file for each iso-
late, and quality control was performed using Trimmomatic (version 0.39) [103] with the
following settings: LEADING:27 TRAILING:27 SLIDINGWINDOW:4:27 MINLEN:35. Muta-
tions were then identified using breseq (version 0.34.1) [104]. The annotated reference genome
for P. aeruginosaUCBPP-PA14 was obtained from BioProject accession number
PRJNA38507. For B.multivorans AU42096, no reference genome was available from NCBI.
Therefore, a genome scaffold was assembled from the paired-end sequencing data for the par-
ent strain using SPAdes (version 3.14.0) with default parameters [105]. This scaffold was then
used as the reference for breseq. Differences between the parent strain and isolates were identi-
fied using the gdtools utility that comes with breseq to compare the respective breseq outputs.
All sequenced P. aeruginosamutants were derived from the Δphz strain except for CipR-33
and CipR-40, which were derived from the WT strain. In the case of B.multivorans, several
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dozen putative mutations were identified that were common to all 3 sequenced putative
mutants. We assumed that these represented assembly errors in the parent strain genome scaf-
fold, but even if they were genuine mutations, these would not account for the phenotypic dif-
ferences between the isolates; therefore, S6 Table reports only mutations that were unique to
each isolate. The genomic loci containing each putative mutation for the B.multivorans iso-
lates were identified by retrieving the surrounding 200 bp from the parent genome scaffold
and using the nucleotide BLAST tool on the MicroScope platform [106] to find the closest
match in the B.multivorans ATCC 17616 genome.
Growth curves with propidium iodide
To verify that PYO did not increase the population turnover rate (i.e., cell death) in our log-
phase fluctuation tests prior to the antibiotic selection step, we performed growth curves in the
presence of different concentrations of PYO, with the addition of PI as a fluorescent marker
for cell death. The use of PI as a marker for PYO-induced cell death has previously been vali-
dated under similar conditions [16]. The growth curves were performed in GMM and SCFM
for P. aeruginosa Δphz and GMM + AA for B.multivorans 1. The cultures were prepared and
incubated in the same manner as the fluctuation tests, except that 5 μM PI was added at the
beginning of the experiment, and measurements for OD500 and PI fluorescence (ex = 535 nm,
em = 617 nm) were taken periodically using a Spark 10M plate reader (Tecan US, Morrisville,
North Carolina, USA). Importantly, PI stock concentration (5 mM, 1,000×) was prepared in
DMSO, and the final concentration of DMSO in the cultures did not exceed 0.1%. In addition,
black 96-well plates with clear bottoms were used to minimize the effects of adjacent wells on
fluorescence readings.
Statistical analyses
All statistical analyses were performed using R [94]. Welch unpaired t tests or 1-way analysis
of variance (ANOVA) with post hoc Tukey honestly significant difference (HSD) test for mul-
tiple comparisons were used for tolerance assay data. The likelihood ratio test as implemented
by the rSalvador function LRT.LD.plating was used to compare mutation rates, alongside the
alternative criterion of nonoverlapping 84% confidence intervals as a proxy for the p< 0.05
threshold for statistical significance. The Mann–Whitney U test was used to compare the dis-
tributions of mutant frequencies. Welch unpaired t tests were used for comparisons of CFU
recovery on ciprofloxacin plates under different PYO treatments. Benjamini–Hochberg cor-
rections were used in all cases to control false discovery rates, except where Tukey HSD test
was performed. For all antibiotic tolerance assays measured by CFUs, survival data were log10
transformed before statistical analyses.
Supporting information
S1 Fig. Effects of different concentrations of PYO on the expression of the P. aeruginosa
oxidative stress response genes ahpB and katB. (A) Normalized cDNA levels measured by
qRT-PCR. cDNA measurements were normalized by levels of the housekeeping gene oprI (see
Methods). (B) Fold change in expression upon PYO treatment, relative to the measurements
in untreated Δphz. ahpB: alkyl hydroperoxide reductase B; katB: catalase B. Black horizontal
lines mark the mean value for independent biological cultures (n = 3). The data underlying
this figure can be found in Table G in S1 Data. PYO, pyocyanin; qRT-PCR, quantitative
reverse transcriptase PCR.
(TIF)
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S2 Fig. Effects of PYO on the expression of P. aeruginosa RND efflux systems (normalized
cDNA levels). The normalized cDNA levels for genes within operons coding for the 11 main
RND efflux systems in P. aeruginosa are shown. cDNA levels for each gene were measured by
qRT-PCR during early stationary phase and normalized by the levels of the housekeeping gene
oprI (see Methods). This dataset was used to make the heatmap presented in Fig 2B. Black hor-
izontal lines mark the mean value for independent biological cultures (n = 3). The data under-
lying this figure can be found in Table H in S1 Data. PYO, pyocyanin; qRT-PCR, quantitative
reverse transcriptase PCR; RND, resistance-nodulation-division.
(TIF)
S3 Fig. Effects of PYO on the expression of P. aeruginosa RND efflux systems (fold
change). The PYO-induced changes in expression for genes within operons coding for the 11
main RND efflux systems in P. aeruginosa are shown. These plots are derived from the normal-
ized cDNA dataset shown in S2 Fig. Here, the values for Δphz were used as the basis for calcu-
lation of changes of expression (shown as log2 fold change). Black horizontal lines mark the
mean value for independent biological cultures (n = 3). The data underlying this figure can be
found in Table H in S1 Data. PYO, pyocyanin; RND, resistance-nodulation-division.
(TIF)
S4 Fig. Effects of PYO on P. aeruginosa tolerance to different antibiotics. (A) Experimental
design for survival assay to measure tolerance to clinical antibiotics. In conditions with exoge-
nous PYO, the PYO was added when cultures were inoculated. PYO itself was not lethal under
these experimental conditions (see panel C in this Fig). (B) Tolerance levels of Δphz cells har-
vested in log phase, following growth in GMM in the presence or absence of PYO (100 μM), to
different aminoglycosides and fluoroquinolones (GEN, TOB, CIP, and LVX). Data points rep-
resent replicates (n = 4 for all except tobramycin, for which n = 3). Stationary-phase tolerance
experiments in GMM are not shown for the aminoglycosides (GEN and TOB), as treatment
with TOB in stationary phase under our conditions at this clinically relevant concentration
[32] did not result in cell death, regardless of the presence of PYO. However, for experiments
performed with stationary-phase cells in SCFM, killing did happen (see Fig 2D). (C) Represen-
tative data showing CFUs counted for Δphz grown for 20 hours (in GMM, see Methods) in the
presence and absence of PYO in our tolerance assays, showing that PYO itself was not toxic
under the studied conditions (n = 4). These are the CFUs for the negative control (no antibi-
otic) for the experiment performed with CIP in Fig 2C. (D) Experimental design for time-
lapse microscopy experiments, in which cells were grown on agarose pads after exposure to
CIP (10 μg/mL) in GMM. The strain/fluorescent protein examples shown (i.e., WT::mApple,
Δphz::GFP) are the ones used in the images of Fig 2F and S1 Movie. (E) Quantification of
microscopy data as done in Fig 2G, but for the experiment with swapped fluorescent proteins.
(F) Experiment quantifying how PYO affects lag for CFUs appearing after treatment with CIP
(10 μg/mL, see Methods) in GMM. Treating P. aeruginosa cells with 10 μg/mL resulted in high
killing levels (see panel G), and we observed an increased lag in the absence of PYO (this sup-
ports microscopy data presented in Figs 2F and 2G and S4E Fig). The survival levels were cal-
culated for CFUs counted after 2 days (too early, since more CFUs appeared later, changing
the calculated survival levels) and 7 days (no CFUs appeared after this time point; correct sur-
vival rate) of the LB plates incubation. Few new CFUs arose for WT and Δphz+PYO treatments
after 2 days, while several appeared for Δphz. Numbers represent the mean survival ratio of
WT/Δphz and Δphz+PYO/Δphz. For survival calculated after 2 days, PYO’s presence gave the
impression of an approximately 10-fold higher survival rate. However, this was mostly due to
lag of Δphz, and the real survival difference was around approximately 2- to 3-fold (calculated
after 7 days) (n = 4). (G) Effects of the efflux inhibitor PAβN on tolerance levels to CIP of Δphz
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cells grown in GMM in the presence or absence of PYO (100 μM). Cultures were treated with
low (left) and high (right) CIP concentrations. Experiments for all the conditions were done in
parallel (see Methods for full protocol) (n = 4). Statistics: B, C, E, G—Welch unpaired t tests. F
—1-way ANOVA with Tukey HSD multiple comparison test, with asterisks showing the statis-
tical significance of comparisons with the Δphz (no PYO) (� p< 0.05, �� p< 0.01, ���
p< 0.001, n.s. p> 0.05). Black horizontal lines mark the mean value for independent cultures
(or fields of view, for E). The data underlying this figure can be found in Table I in S1 Data.
ANOVA, analysis of variance; CFU, colony-forming unit; CIP, ciprofloxacin; GEN, gentami-
cin; GMM, glucose minimal medium; HSD, honestly significant difference; LVX, levofloxacin;
PAβN, phenylalanine-arginine β-naphthylamide; PYO, pyocyanin; TOB, tobramycin; WT,
wild-type.
(TIF)
S5 Fig. Artificial induction of mexGHI-opmD, ahpB, and katB. (A) Normalized cDNA levels
measured by qRT-PCR. cDNA levels were normalized by the housekeeping gene oprI. (B)
Fold change in expression upon arabinose induction. This dataset can be compared to the
PYO-mediated induction of the same genes as shown in Fig 2B and S1–S3 Figs. The 4 strains
shown are (1) the parent Δphz (white background); (2) Δphz Para:mexGHI-opmD (magenta
background); (3) Δphz Para:ahpB (green background); and (4) Δphz Para:katB (blue back-
ground). +/− represent addition or not of 20 mM arabinose to the cultures for the artificial
induction of expression. For additional experimental details and strain information, see Meth-
ods and S5 Table. Black horizontal lines mark the mean value for independent biological cul-
tures (n = 3). The data underlying this figure can be found in Table J in S1 Data. PYO,
pyocyanin; qRT-PCR, quantitative reverse transcriptase PCR.
(TIF)
S6 Fig. Effect of artificial induction of PYO-induced genes on tolerance to CIP. Survival rel-
ative to the no-antibiotic control is shown for the parent Δphz strain and the 3 arabinose-
inducible strains (in which the PYO-inducible genesmexGHI-opmD, ahpB, or katB are under
control of an arabinose-inducible promoter) grown in the presence or absence of 20 mM arab-
inose, without exposure to PYO. The tolerance experiments were performed for cultures in
both log phase (A, n = 3) and stationary phase (B, n = 4) in GMM. In B, the experiment for
mexGHI-opmD is the same as in Fig 2I but is also shown here for ease of comparison. Statistics:
Welch unpaired t tests (� p< 0.05, �� p< 0.01, ��� p< 0.001, n.s. p> 0.05). Black horizontal
lines mark the mean value for independent cultures. The data underlying this figure can be
found in Table K in S1 Data. CIP, ciprofloxacin; GMM, glucose minimal medium; PYO, pyo-
cyanin.
(TIF)
S7 Fig. Effect of PYO or PYO-induced genes on apparent mutation rates in P. aeruginosa.
(A) Apparent mutation rates of stationary-phase Δphz grown in liquid GMM and plated onto
MH agar containing CIP (0.5 μg/mL), with or without pre- and/or co-exposure to 100 μM
PYO relative to the antibiotic selection step (n = 8). (B-C) Apparent mutation rates of log-
phase cells grown in GMM and plated onto MH agar containing CIP (0.5 μg/mL), with or
without pre- and/or co-exposure to 20 mM arabinose relative to the antibiotic selection step.
Data are shown for Δphz Para:mexGHI-opmD alone (B, left, n = 4) and in comparison to Δphz
(B, right) or Δphz Para:katB and Δphz Para:ahpB (C, n = 4). In all panels, each data point repre-
sents 44 parallel cultures from a single biological replicate, and the vertical lines represent 84%
confidence intervals, for which lack of overlap corresponds to statistical significance at the
p< 0.05 level [99]. The PYO treatments correspond to the following: −/− denotes no PYO
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pretreatment (in the liquid culture stage) or co-treatment (in the antibiotic agar plates),
+/− denotes PYO pretreatment but no co-treatment, −/+ denotes PYO co-treatment without
pretreatment, and +/+ denotes both PYO pretreatment and co-treatment. The data underlying
this figure can be found in Table L in S1 Data. CIP, ciprofloxacin; GMM, glucose minimal
medium; MH, Mueller–Hinton; PYO, pyocyanin.
(TIF)
S8 Fig. Effect of PYO on resistance phenotypes and antibiotic tolerance of P. aeruginosa
mutants. (A) The percentage of CFUs recovered on CIP (0.5 μg/mL) either with or without
100 μM PYO in the agar, for log-phase cultures of representative resistant mutants of P.a. that
were not enriched by exposure to PYO in the fluctuation tests. The mutants were pre-grown
with or without 100 μM PYO in GMM before plating. On the x-axis, “pre” denotes the pres-
ence of PYO in the liquid cultures and “co” denotes the presence of PYO in the agar plates.
Percentage recovery was calculated relative to total CFUs counted on nonselective plates
(n = 4). (B) Tolerance to CIP (1 μg/mL) of partially resistant mutants grown in GMM to sta-
tionary phase with or without 100 μM PYO (n = 4). Experiments were performed as shown in
S5A Fig. (C) The percentage of CFUs recovered on CIP (0.5 μg/mL) for log-phase cultures of
representative resistant mutants that were enriched by exposure to PYO in the fluctuation tests
(n = 4). Experiments were performed in the same way as in panel A. (D, E) Growth curves per-
formed for P. aeruginosa Δphz (P.a.) and B.multivorans 1 (B.m.) in GMM (with the addition
of AA for B.multivorans; see Methods) or SCFM, with different concentrations of PYO in the
presence of 5 μM PI, which is a fluorescent marker for cell death. OD500 (cell density) is plotted
in G, while PI fluorescence is plotted in H. Gray shaded regions represent the standard devia-
tion of 4 biological replicates. In G, the dashed horizontal lines mark the cell density at which
P. aeruginosa (lower line in left panel) or B.multivorans (upper line in left panel) would have
been plated in our fluctuation tests. Note that these OD500 values differ from those reported in
the Methods section for fluctuation tests due to the use of a microtiter plate reader in this
experiment, whereas a different spectrophotometer was used in the fluctuation tests. In H, the
vertical dashed lines mark the time at which the cultures would have been plated in the fluctua-
tion tests (in the left panel, left line = B.m. sampling time, right line = P.a. sampling time). The
increase in fluorescence seen for B.multivorans prior to stationary phase likely reflects the pro-
duction of a fluorescent metabolite rather than early cell death, as fluorescence was initially
higher for the cultures not treated with PYO and the exponential phase growth rates were
identical regardless of PYO treatment. Statistics: A–C—Welch unpaired t tests (� p< 0.05, ��
p< 0.01, ��� p< 0.001, n.s. p> 0.05). Unless indicated otherwise with brackets, statistical sig-
nificance is shown for the comparison with the untreated (no PYO) condition. In A–C, data
points represent independent biological cultures, with horizontal black lines marking the
mean value for each condition. The data underlying this figure can be found in Table M in S1
Data. AA, amino acid; CFU, colony-forming unit; GMM, glucose minimal medium; P.a., P.
aeruginosa; PI, propidium iodide; PYO, pyocyanin; SCFM, synthetic cystic fibrosis sputum
medium.
(TIF)
S9 Fig. Goodness of fit of different mathematical models for P. aeruginosa Δphz fluctua-
tion test data. Data are plotted for different combinations of PYO in liquid (pretreatment)
and PYO in agar (co-exposure to antibiotic selection). The empirical CDFs of the data (black)
are plotted against (1) a variation of the LD model fit with 2 parameters,m (the expected num-
ber of mutations per culture) and w (the relative fitness of mutant cells vs. WT), as imple-
mented by Hamon and Ycart [44] (pink); (2) a mixed LD and Poisson distribution fit with 2
parameters,m and d (the number of generations that occur post-plating), allowing for the
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possibility of post-plating mutations, as implemented by Lang and colleagues [45] (blue); (3)
the basic LD distribution model fit only withm, as implemented by Lang and colleagues [45]
(gray). In each condition, the plotted data represent the biological replicate with the lowest
chi-squared goodness of fit p-value (i.e., least good fit) for the Hamon and Ycart model. The
data underlying this figure can be found in Table N in S1 Data. CDF, cumulative distribution
function; GEN, gentamicin; LD, Luria–Delbrück; LVX, levofloxacin; PYO, pyocyanin; TOB,
tobramycin; WT, wild-type.
(TIF)
S1 Table. Read ratios for each gene (PA14 genome) in the PYO tolerance Tn-seq experi-
ment. Analysis was done using ARTIST software (see Methods). Ratios = reads + PYO condi-
tions / reads no PYO condition (log2 transformed), where high ratio values = increased fitness
and low ratio values = decreased fitness. CIP Tn-seq values are from Cameron and colleagues
[24] (see Methods). NA, not applicable. NR, not reported, meaning that there were no reads
from the gene/locus within the replicate (or in at least one of the replicates, when displayed in
the “average log2-transformed ratio” column). CIP, ciprofloxacin; PYO, pyocyanin; Tn-seq,
transposon sequencing.
(XLSX)
S2 Table. Statistical significance of comparisons of mutation rates and mutant frequencies.
Mutation rates reported in this table were calculated using the rSalvador function newton.LD.
plating and were compared using the LRT.LD.plating function to determine statistical signifi-
cance. Mutant frequencies were compared using the Mann–Whitney U test. Reported p-values
were adjusted with the Benjamini–Hochberg correction to control the false discovery rate. LD,
Luria–Delbrück; LRT, likelihood ratio test.
(XLSX)
S3 Table. Fluctuation test analysis results for all log-phase experiments conducted in mini-
mal medium. Model parameters: μ, apparent mutation rate per generation; m, expected num-
ber of mutational events per cultures; w, fitness ratio of mutants/WT; d, number of post-
plating generations. See Methods for details on the different mathematical models. CIP, cipro-
floxacin; GEN, gentamicin; HY, Hamon and Ycart; LD, Luria–Delbrück; LRT, likelihood ratio
test; LVX, levofloxacin; score, negative log likelihood; TOB, tobramycin. WT, wild-type.
(XLSX)
S4 Table. Mutations detected in CIP-resistant isolates of Pseudomonas aeruginosa PA14.
Mutations were detected using breseq, with the reference set as the P. aeruginosa
UCBPP-PA14 genome obtained from BioProject accession number PRJNA38507. Pseudo-
genes and synonymous substitution mutations were omitted from the table. CIP, ciprofloxa-
cin.
(XLSX)
S5 Table. Strains, plasmids, and primers used in this study. This table contains a list of the
strains, plasmids, and primers used in this study.
(XLSX)
S6 Table. Mutations detected in partially CIP-resistant isolates of Burkholderia multivor-
ans AU42096. Mutations were detected using breseq, with a draft assembly of the genome for
B.multivorans AU42096 as the reference. Only mutations unique to each isolate are included.
CIP, ciprofloxacin.
(XLSX)
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S7 Table. CIP MICs for fluctuation test isolates and parent strains. MICs were determined
in a microbroth dilution assay according to standard clinical methods (see Methods). Where a
range of values is presented, this indicates that the observed MIC sometimes varied depending
on the initial cell density of the inoculum, even within the clinically acceptable range of
3–7 × 105 CFUs/mL. CFU, colony-forming unit; CIP, ciprofloxacin; MIC, minimum inhibi-
tory concentration.
(XLSX)
S1 Movie. PYO effect on lag during outgrowth after exposure to CIP. Four time points of
this movie are shown in Fig 2F. For experimental details, see Fig 2F and Methods. WT cells
(PYO producers, expressing mApple) are shown in magenta, while Δphz cells (PYO nonpro-
ducers, expressing GFP) are shown in green. Recovery in the absence of PYO after exposure to
ciprofloxacin was imaged every 15 minutes for 15 hours. Scale bar: 20 μm. CIP, ciprofloxacin;
PYO, pyocyanin; WT, wild-type.
(MP4)
S1 Data. Raw data and code for reproducing all main and supporting figures. This zipped
folder contains Excel tables organized by figure, within which the raw data for individual pan-
els are displayed in separate tabs, as well as a text file containing the R code for all functions
that were written especially for this manuscript.
(ZIP)
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